{
  "symbol": "IRIX",
  "company_name": "Iridex Corp",
  "ir_website": "https://iridex.gcs-web.com/",
  "structured_data": [
    {
      "section_name": "News",
      "links": [
        {
          "title": "Iridex Comments on Changing Glaucoma Reimbursement Landscape",
          "url": "https://iridex.gcs-web.com/news-releases/news-release-details/iridex-comments-changing-glaucoma-reimbursement-landscape",
          "content": "[ Skip to main navigation ](#main-menu)\n\n![Iridex Logo](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/iridex-logo-tag.png)\n\n[Company](http://www.iridex.com/company.aspx) [Investors](/) [Find a Physician](http://www.iridex.com/fap) [News](https://iridex.gcs-web.com/news-releases?field_nir_news_date_value\\[min\\]=2020#views-exposed-form-widget-news-widget-news-ul) [Careers](https://iridex.com/careers.aspx) [Germany](http://www.iridex.de) [Search](http://www.iridex.com/IridexSearch.aspx)\n\nSales: 650-940-4700 \n\nSupport: (800) 388-4747 [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/facebook-top-icon.png)](http://www.facebook.com/IRIDEX) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/twitter-top-icon.png)](http://twitter.com/iridex) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/linkedin-top-icon.png)](http://www.linkedin.com/company/iridex) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/youtube-top-icon.png)](http://www.youtube.com/user/IRIDEXophthalmology) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/insta.jpg)](https://www.instagram.com/iridex_glaucoma)\n\n  * [Home](http://www.iridex.com/Default.aspx?tabid=56)\n  * [Products](http://www.iridex.com/Default.aspx?tabid=58)\n    * [Lasers](http://www.iridex.com/Default.aspx?tabid=102)\n      * [Cyclo G6](http://iridex.com/Products/Lasers/CYCLOG6MicroPulseP3.aspx)\n      * [IQ 532](https://iridex.com/Default.aspx?tabid=103)\n      * [IQ 577](https://iridex.com/Default.aspx?tabid=104)\n      * [OcuLight](https://iridex.com/Default.aspx?tabid=132)\n    * [Retina Delivery Devices](https://iridex.com/Default.aspx?tabid=107)\n      * [LIO](https://iridex.com/Default.aspx?tabid=384)\n      * [TxCell](https://iridex.com/Products/LaserDeliveryDevices/GlaucomaDevices/micropulsep3.aspx)\n    * [Glaucoma Devices](http://www.iridex.com/Default.aspx?tabid=184)\n      * [MicroPulse P3 Device](http://iridex.com/Products/Lasers/CYCLOG6MicroPulseP3.aspx)\n      * [Revised MicroPulse P3](https://iridex.com/Products/GlaucomaDevices/micropulsep3.aspx)\n      * [G-Probe](http://iridex.com/Default.aspx?tabid=112)\n      * [G-Probe Illuminate](http://iridex.com/Default.aspx?tabid=314)\n      * [MicroPulse Laser Trabeculoplasty (MLT) Lens](http://iridex.com/Default.aspx?tabid=178)\n    * [Retinal Surgical Instruments](http://iridex.com/Default.aspx?tabid=89)\n      * [Laser Probes](http://iridex.com/Default.aspx?tabid=208)\n      * [Consumables](http://iridex.com/Default.aspx?tabid=182)\n    * [Veterinary](http://www.iridex.com/Default.aspx?tabid=101)\n    * [ENT](http://www.iridex.com/Default.aspx?tabid=113)\n    * [Accessories](http://www.iridex.com/Default.aspx?tabid=350)\n      * [Vexio Cart](http://www.iridex.com/Default.aspx?tabid=351)\n  * [MicroPulse](http://www.iridex.com/Default.aspx?tabid=86)\n  * [Physician Education](http://www.iridex.com/Default.aspx?tabid=84)\n    * [Glaucoma](http://www.iridex.com/Default.aspx?tabid=158)\n      * [Library](http://www.iridex.com/Default.aspx?tabid=362)\n      * [MicroPulse P3 - CYCLO G6](http://www.iridex.com/Default.aspx?tabid=228)\n      * [TSCPC G-Probe](http://www.iridex.com/Default.aspx?tabid=120)\n      * [Trabeculoplasty (MLT)](http://www.iridex.com/Default.aspx?tabid=123)\n    * [Retina](http://www.iridex.com/Default.aspx?tabid=159)\n      * [Age-Related Macular Degeneration](http://www.iridex.com/Default.aspx?tabid=258)\n      * [Central Serous Chorioretinopathy](http://www.iridex.com/Default.aspx?tabid=149)\n      * [Diabetic Macular Edema ](http://www.iridex.com/Default.aspx?tabid=117)\n      * [ME due to RVOs](http://www.iridex.com/Default.aspx?tabid=161)\n      * [ROP](http://www.iridex.com/Default.aspx?tabid=202)\n      * [Vitreoretinal Surgery](http://www.iridex.com/Default.aspx?tabid=118)\n    * [Testimonials](http://www.iridex.com/Default.aspx?tabid=299)\n    * [Certification](http://www.iridex.com/Default.aspx?tabid=376)\n    * [Webinars](http://www.iridex.com/Default.aspx?tabid=288)\n    * [Seminars](http://www.iridex.com/Default.aspx?tabid=292)\n    * [Articles](http://www.iridex.com/Default.aspx?tabid=346)\n    * [Clinical Library](javascript:void\\(window.open\\('https://iridexsupport.zendesk.com/hc/en-us'\\)\\))\n    * [Reimbursement Calculator](http://www.iridex.com/Default.aspx?tabid=190)\n    * [Manuals](http://www.iridex.com/Default.aspx?tabid=385)\n  * [Patient Education](http://www.iridex.com/Default.aspx?tabid=85)\n    * [Treat My DME](javascript:void\\(window.open\\('http://treatmydme.com/'\\)\\))\n    * [Treat My Glaucoma](javascript:void\\(window.open\\('http://treatmyglaucoma.com/'\\)\\))\n    * [Find A Physician](http://www.iridex.com/Default.aspx?tabid=155)\n  * [Contact](http://www.iridex.com/Default.aspx?tabid=137)\n    * [Contact Us](http://www.iridex.com/Default.aspx?tabid=91)\n    * [Ask A Question](http://www.iridex.com/Default.aspx?tabid=92)\n    * [Schedule A Demo](http://www.iridex.com/Default.aspx?tabid=93)\n    * [Request A Quote](http://www.iridex.com/Default.aspx?tabid=94)\n    * [Order EndoProbe®](http://www.iridex.com/order-endoprobes/index.html)\n    * [International Distributors](http://www.iridex.com/Default.aspx?tabid=116)\n\n\n\n# Press Release\n\n<< [Back](#) Iridex Comments on Changing Glaucoma Reimbursement Landscape MOUNTAIN VIEW, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today confirms that Local Coverage Determination (LCD) L37531, relating to Micro-Invasive Glaucoma Surgery (MIGS), was adopted as scheduled and will be effective for services performed on or after November 17, 2024. The Company has previously reported that it believes the reimbursement limitations created by the new LCD has potential to significantly increase physician interest in and use of Iridex’s advanced laser-based treatments for glaucoma. The new LCD clarifies that treatments performed using Iridex’s laser consoles and probes are not MIGS procedures, and thus, Iridex’s Cyclo G6® product family is unaffected by the new reimbursement limitations. Iridex’s proprietary MicroPulse® and Continuous Wave laser therapies for glaucoma have been adopted by physicians around the globe as effective tools for managing and slowing the progression of glaucoma. Currently, Iridex sells more than 50,000 Cyclo G6 probes per year. “In addition to creating some reimbursement advantages for Iridex’s glaucoma treatments in the United States, the LCD creates opportunity to capture more physician attention to the significant clinical benefits of our products, particularly MicroPulse Transscleral Laser Therapy (MPTLT),” said Kevin LaMarche, Iridex’s Senior Director of Clinical Affairs. “Our laser procedures are noninvasive, repeatable, and can be utilized to treat patients across a far broader range of glaucoma’s progression, whether before, after, or even coincident to MIGS procedures.” Nathan M Radcliffe, MD, of New York Eye and Ear Infirmary, commented, “Glaucoma is a non-curable disease. It is important that we have coverage for as many glaucoma treatments as possible. Transscleral Cyclophotocoagulation (TSCPC) is one of the very few glaucoma procedures that can be utilized in several disease states and almost all glaucoma types. Thousands of patients could have faced permanent blindness were this procedure limited by coverage.” Brian A Francis, MD, Associate Professor of Ophthalmology at the Doheny Eye Institute, added, “I am encouraged that TSCPC remains unaffected by the recent glaucoma LCD. TSCPC is a valuable and versatile laser therapy within the glaucoma treatment paradigm.” The final LCD, L37531, which went into effect on November 17, 2024, provides the following reimbursement limitations:\n\n  1. MIGS is not considered a first line treatment for mild-moderate glaucoma.\n  2. A combination of a surgical MIGS procedure and an aqueous shunt cannot be performed at the same time of service in the same eye.\n  3. Phacoemulsification/intraocular lens placement performed with a combination of MIGS procedures, (e.g., cataract + stent + canaloplasty or goniotomy) at the same time of service in the same eye is non-covered.\n\nPatrick Mercer, Iridex’s CEO, commented on the implications of the LCD for physicians treating glaucoma, “The community has been focused on pursuing more MIGS procedures, even to the point of stacking one form of treatment on top of another. The LCD appears designed to end this, and physicians evaluating treatment options will increasingly look for non-MIGS procedures, such as Iridex’s MicroPulse and Continuous Wave TLT, as they seek to mitigate progression of the disease.” Mr. Mercer continued, “At the recent American Academy of Ophthalmology (AAO) conference in Chicago, we saw significant anecdotal evidence that physicians already appreciate the increased role Iridex’s Cyclo G6 product family will play in their practices. We observed a steady stream of physicians visiting our booth and participating in our wet lab trainings that initiated discussion with our clinical and sales representatives on their intention to increase the number of MicroPulse and Continuous Wave TLT procedures they will perform. We are very encouraged by these developments,” Mr. Mercer concluded. **About Iridex Corporation ** Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at [www.iridex.com](http://www.iridex.com). MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2024 Iridex Corporation. All rights reserved. **Safe Harbor Statement** This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning clinical expectations and commercial trends, market adoption and expansion, value-maximizing transactions, demand for and utilization of the Company's products and results and expected sales volumes. The Company can provide no assurance that it will complete any value-maximizing transactions on behalf of its stockholders. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2024. Forward-looking statements contained in this announcement are made as of this date and will not be updated. **Investor Relations Contact** Philip TaylorGilmartin Groupinvestors@iridex.com![](https://www.globenewswire.com/newsroom/ti?nf=OTI3NjQwMyM2NTg5OTg4IzIwMDkxMDk=)![](https://ml.globenewswire.com/media/ZjFiMGNlMjEtMTI0Zi00NmIwLTg4MWQtMzRkZDYxYTk4MTMzLTEwMjA2ODI=/tiny/IRIDEX-Corporation.png)[![Primary Logo](https://ml.globenewswire.com/media/2bb80159-a920-428b-aa69-c2f32e3038c9/small/iridex-corporate-logo-horizontal-rgb-m02-jpg.jpg)](https://www.globenewswire.com/NewsRoom/AttachmentNg/2bb80159-a920-428b-aa69-c2f32e3038c9) Source: IRIDEX Corporation  \n---  \n  \n##  Products\n\n[Lasers](http://www.iridex.com/Products/Lasers.aspx) [Delivery Devices](http://www.iridex.com/Products/DeliveryDevices.aspx) [Retina Consumables](http://www.iridex.com/Products/RetinaConsumables.aspx) [Glaucoma Device](http://www.iridex.com/Products/GlaucomaConsumables/G-Probe.aspx) | \n\n## Resources\n\n[Physician Information](http://www.iridex.com/PhysicianEducation.aspx) [Patient Information](http://www.iridex.com/PatientEducation.aspx) [Clinical Library](http://www.iridex.com/PhysicianEducation/ClinicalLibrary.aspx) | \n\n## About IRIDEX\n\n[Overview](http://www.iridex.com/Company/tabid/95/Default.aspx) [News](http://www.iridex.com/News.aspx) [Events](http://www.iridex.com/Events.aspx) [Contact Us](http://www.iridex.com/Contact.aspx) | \n\n## Company\n\n[Investors](/) [Offices/Contact](http://www.iridex.com/Contact/InternationalDistributors.aspx) [Careers](http://www.iridex.com/Company/Careers/tabid/96/Default.aspx)  \n---|---|---|---  \n[![twitter](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-twitter.jpg)](http://twitter.com/iridex) [![facebook](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-fb.jpg)](http://www.facebook.com/IRIDEX) [![linkedin](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-linkedin.jpg)](http://www.linkedin.com/company/iridex) [![youtuber](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-youtube.jpg)](http://www.youtube.com/user/IRIDEXCorp)  \n---  \n  \nCopyright 2024 by Iridex Corporation\n\n[Terms Of Use](http://www.iridex.com/terms.aspx) | [Privacy Statement](http://www.iridex.com/privacy.aspx)\n"
        },
        {
          "title": "Iridex Reports Third Quarter 2024 Financial Results",
          "url": "https://iridex.gcs-web.com/news-releases/news-release-details/iridex-reports-third-quarter-2024-financial-results",
          "content": "[ Skip to main navigation ](#main-menu)\n\n![Iridex Logo](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/iridex-logo-tag.png)\n\n[Company](http://www.iridex.com/company.aspx) [Investors](/) [Find a Physician](http://www.iridex.com/fap) [News](https://iridex.gcs-web.com/news-releases?field_nir_news_date_value\\[min\\]=2020#views-exposed-form-widget-news-widget-news-ul) [Careers](https://iridex.com/careers.aspx) [Germany](http://www.iridex.de) [Search](http://www.iridex.com/IridexSearch.aspx)\n\nSales: 650-940-4700 \n\nSupport: (800) 388-4747 [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/facebook-top-icon.png)](http://www.facebook.com/IRIDEX) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/twitter-top-icon.png)](http://twitter.com/iridex) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/linkedin-top-icon.png)](http://www.linkedin.com/company/iridex) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/youtube-top-icon.png)](http://www.youtube.com/user/IRIDEXophthalmology) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/insta.jpg)](https://www.instagram.com/iridex_glaucoma)\n\n  * [Home](http://www.iridex.com/Default.aspx?tabid=56)\n  * [Products](http://www.iridex.com/Default.aspx?tabid=58)\n    * [Lasers](http://www.iridex.com/Default.aspx?tabid=102)\n      * [Cyclo G6](http://iridex.com/Products/Lasers/CYCLOG6MicroPulseP3.aspx)\n      * [IQ 532](https://iridex.com/Default.aspx?tabid=103)\n      * [IQ 577](https://iridex.com/Default.aspx?tabid=104)\n      * [OcuLight](https://iridex.com/Default.aspx?tabid=132)\n    * [Retina Delivery Devices](https://iridex.com/Default.aspx?tabid=107)\n      * [LIO](https://iridex.com/Default.aspx?tabid=384)\n      * [TxCell](https://iridex.com/Products/LaserDeliveryDevices/GlaucomaDevices/micropulsep3.aspx)\n    * [Glaucoma Devices](http://www.iridex.com/Default.aspx?tabid=184)\n      * [MicroPulse P3 Device](http://iridex.com/Products/Lasers/CYCLOG6MicroPulseP3.aspx)\n      * [Revised MicroPulse P3](https://iridex.com/Products/GlaucomaDevices/micropulsep3.aspx)\n      * [G-Probe](http://iridex.com/Default.aspx?tabid=112)\n      * [G-Probe Illuminate](http://iridex.com/Default.aspx?tabid=314)\n      * [MicroPulse Laser Trabeculoplasty (MLT) Lens](http://iridex.com/Default.aspx?tabid=178)\n    * [Retinal Surgical Instruments](http://iridex.com/Default.aspx?tabid=89)\n      * [Laser Probes](http://iridex.com/Default.aspx?tabid=208)\n      * [Consumables](http://iridex.com/Default.aspx?tabid=182)\n    * [Veterinary](http://www.iridex.com/Default.aspx?tabid=101)\n    * [ENT](http://www.iridex.com/Default.aspx?tabid=113)\n    * [Accessories](http://www.iridex.com/Default.aspx?tabid=350)\n      * [Vexio Cart](http://www.iridex.com/Default.aspx?tabid=351)\n  * [MicroPulse](http://www.iridex.com/Default.aspx?tabid=86)\n  * [Physician Education](http://www.iridex.com/Default.aspx?tabid=84)\n    * [Glaucoma](http://www.iridex.com/Default.aspx?tabid=158)\n      * [Library](http://www.iridex.com/Default.aspx?tabid=362)\n      * [MicroPulse P3 - CYCLO G6](http://www.iridex.com/Default.aspx?tabid=228)\n      * [TSCPC G-Probe](http://www.iridex.com/Default.aspx?tabid=120)\n      * [Trabeculoplasty (MLT)](http://www.iridex.com/Default.aspx?tabid=123)\n    * [Retina](http://www.iridex.com/Default.aspx?tabid=159)\n      * [Age-Related Macular Degeneration](http://www.iridex.com/Default.aspx?tabid=258)\n      * [Central Serous Chorioretinopathy](http://www.iridex.com/Default.aspx?tabid=149)\n      * [Diabetic Macular Edema ](http://www.iridex.com/Default.aspx?tabid=117)\n      * [ME due to RVOs](http://www.iridex.com/Default.aspx?tabid=161)\n      * [ROP](http://www.iridex.com/Default.aspx?tabid=202)\n      * [Vitreoretinal Surgery](http://www.iridex.com/Default.aspx?tabid=118)\n    * [Testimonials](http://www.iridex.com/Default.aspx?tabid=299)\n    * [Certification](http://www.iridex.com/Default.aspx?tabid=376)\n    * [Webinars](http://www.iridex.com/Default.aspx?tabid=288)\n    * [Seminars](http://www.iridex.com/Default.aspx?tabid=292)\n    * [Articles](http://www.iridex.com/Default.aspx?tabid=346)\n    * [Clinical Library](javascript:void\\(window.open\\('https://iridexsupport.zendesk.com/hc/en-us'\\)\\))\n    * [Reimbursement Calculator](http://www.iridex.com/Default.aspx?tabid=190)\n    * [Manuals](http://www.iridex.com/Default.aspx?tabid=385)\n  * [Patient Education](http://www.iridex.com/Default.aspx?tabid=85)\n    * [Treat My DME](javascript:void\\(window.open\\('http://treatmydme.com/'\\)\\))\n    * [Treat My Glaucoma](javascript:void\\(window.open\\('http://treatmyglaucoma.com/'\\)\\))\n    * [Find A Physician](http://www.iridex.com/Default.aspx?tabid=155)\n  * [Contact](http://www.iridex.com/Default.aspx?tabid=137)\n    * [Contact Us](http://www.iridex.com/Default.aspx?tabid=91)\n    * [Ask A Question](http://www.iridex.com/Default.aspx?tabid=92)\n    * [Schedule A Demo](http://www.iridex.com/Default.aspx?tabid=93)\n    * [Request A Quote](http://www.iridex.com/Default.aspx?tabid=94)\n    * [Order EndoProbe®](http://www.iridex.com/order-endoprobes/index.html)\n    * [International Distributors](http://www.iridex.com/Default.aspx?tabid=116)\n\n\n\n# Press Release\n\n<< [Back](#) Iridex Reports Third Quarter 2024 Financial Results MOUNTAIN VIEW, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended September 28, 2024. **Third Quarter 2024 Financial and Recent Highlights**\n\n  * Expects to achieve EBITDA breakeven in the fourth quarter of 2024 as a result of actions to reduce costs and improve profitability\n  * Generated total revenue of $11.6 million, representing a decline of 8% sequentially from the second quarter of 2024 and a decline of 10% over Q3’23\n  * Cyclo G6® product family revenue was $3.1 million, representing growth of 3% from the third quarter of 2023 \n    * Sold 13,600 Cyclo G6 probes, compared to 13,200 in the prior year period\n    * Sold 26 Cyclo G6 Glaucoma Laser Systems, compared to 27 in the prior year period\n  * Retina product revenue was $6.5 million, representing a sequential decline of 12% from the second quarter of 2024 and a decline of 18% from the prior year period\n  * Strengthened balance sheet with net proceeds of $3.4 million through convertible note offering funded August 7, 2024\n  * Cash and cash equivalents as of September 28, 2024, was approximately $3.9 million.\n\n**Recent Corporate Highlights**\n\n  * Appointed Patrick Mercer as Chief Executive Officer; previously, Mr. Mercer served as the Company’s Chief Operating Officer and President. In addition, Scott Shuda, who had previously served as Chairman, was appointed Executive Chairman of the Company’s board of directors.\n  * Company’s strategic review ongoing with multiple parties.\n  * New Local Coverage Determinations (LCDs) for Medicare Administrative Contractor (MAC) reimbursement taking effect November 17, 2024 position Iridex’s glaucoma products for increased use.\n\nPatrick Mercer, who was elevated from President and Chief Operating Officer to President and Chief Executive Officer on Iridex effective October 1, 2024, commented, “While the third quarter has traditionally been the quarter subject to the most seasonal softness, we were disappointed to see a return to extended sales cycles in our retina business. Glaucoma though was a highlight, being less dependent on capital equipment sales, with a majority of its revenues comprised of single-use consumable probes, the business experienced stable demand and generated growth over the prior year period in an overall challenging quarter. Moreover, we experienced some shipment delays for certain products due to regulatory hurdles in some territories. However, we expect these regulatory issues to be resolved in the fourth quarter and to begin shipments.” Scott Shuda, Executive Chairman of Iridex, commented on the Company’s strategic review, “I am pleased to report that we have recently achieved meaningful progress and are currently in discussions with multiple parties relating to transaction opportunities. Among other things, the changing reimbursement landscape for glaucoma treatments is bringing favorable attention to Iridex and the value of our efficient and efficacious laser procedures.” **New LCDs Reshaping Glaucoma Reimbursement Landscape** The future potential for Iridex’s MicroPulse® and Continuous Wave laser therapies for glaucoma received a noted boost during the third quarter with the publication of the updated Local Coverage Determinations (LCDs) for Medicare Administrative Contractor (MAC) reimbursement relating to Micro-Invasive Glaucoma Surgery (MIGS).  “Last year, we reported on how Iridex’s glaucoma products had inexplicably become caught up in an earlier LCD, subsequently withdrawn, that was widely interpreted as seeking to limit and likely reduce MIGS procedures,” said Mr. Mercer. “This year, we are pleased to report that Iridex’s glaucoma products are unaffected by a replacement LCD, which again places limitations on reimbursement for MIGS procedures. The final LCD, which goes into effect on November 17, 2024, indicates that MIGS is not considered a first-line treatment for mild to moderate glaucoma, and simultaneous performance of multiple MIGS procedures is not permitted.” “This new reimbursement paradigm has the potential to increase physician adoption of Iridex's glaucoma products,” Mr. Mercer continued. “Our strategy has focused on promoting the use of Iridex technology as a post-combination MIGS procedure. The new LCD opens the door to engaging with physicians to reassess applications for our technology and discuss its potential earlier in the treatment pathway. Particularly, we will encourage clinicians to explore the opportunity to perform cataract surgery in combination with MicroPulse Transscleral Laser Therapy (MPTLT). We believe this represents a compelling treatment option that emphasizes the synergistic benefits of MicroPulse TLT to offer significant clinical advantages, particularly for patients seeking to achieve low intraocular pressure (IOP).” **Actions to Reduce Costs and Improve Profitability** In the fourth quarter of 2024, Iridex implemented a series of additional operating improvements and cost-cutting measures designed to improve its financial performance and increase its balance sheet and working capital efficiency. These initiatives include significant cost reductions across all departments, renegotiating supplier contracts to free up capital, and reducing inventory levels. Additionally, Iridex will engage with global contract manufacturing partners to improve gross margins through increased outsourcing. As a result of these initiatives, Iridex expects to achieve EBITDA breakeven in the fourth quarter of 2024. **Third Quarter 2024 Financial Results** Revenue for the three months ended September 28, 2024, was $11.6 million, representing a sequential decline of 8% from the second quarter of 2024 and a decline of 10% compared to $12.9 million in the same period of the prior year. Retina product revenue decreased to $6.5 million, representing a decline of 12% compared to the second quarter of 2024 and a decline of 18% compared to the prior year period, primarily driven by softness in system sales impacted by the ongoing capital purchasing constraints both domestically and internationally. Due to regulatory delays in certain key international geographies the Company also ended the quarter with a larger-than-normal capital equipment backlog. Total product revenue from the Cyclo G6® Glaucoma product group was $3.1 million, a decrease of $0.2 million compared to the second quarter of 2024 and an increase of $0.1M compared to the third quarter of 2023. Other revenue increased to $2.0 million or 3% in the third quarter of 2024 compared to the prior year period, primarily driven by service and certain legacy product revenue growth. Gross profit for the third quarter of 2024 was $4.3 million, or a 37.3% gross margin, a decrease compared to $5.6 million, or a 43.7% gross margin, in the same period of the prior year. This decrease was driven primarily by lower overhead cost absorption on lower revenue and shifts in product mix.  Operating expenses of $6.2 million in the third quarter of 2024 decreased $1.1 million compared to $7.3 million in the same period of the prior year due to ongoing cost reduction initiatives, despite higher general and administrative expenses related to the company’s strategic process not seen in the prior year period. The net loss for the third quarter of 2024 was $1.9 million, or $0.12 per share, compared to $1.8 million, or $0.11 per share, in the same period of the prior year. Cash and cash equivalents totaled $3.9 million as of September 28, 2024. **Webcast and Conference Call Information** Iridex’s management team will hold a conference call today at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may dial +1-888-596-4144 for domestic callers or +1-646-968-2525 for international callers, using conference ID: 3650755. A live and recorded webcast on the “Event Calendar” page of the “Investors” section of the Company’s website at [www.iridex.com](http://www.iridex.com). **About Iridex Corporation ** Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at [www.iridex.com](http://www.iridex.com). MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2024 Iridex Corporation. All rights reserved. **Safe Harbor Statement** This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning clinical expectations and commercial trends, market adoption and expansion, value-maximizing transactions, demand for and utilization of the Company's products and results and expected sales volumes. The Company can provide no assurance that it will complete any value-maximizing transactions on behalf of its stockholders. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 14, 2024. Forward-looking statements contained in this announcement are made as of this date and will not be updated. **Investor Relations Contact** Philip TaylorGilmartin Groupinvestors@iridex.com | **IRIDEX Corporation**  \n---  \n**Condensed Consolidated Statements of Operations**  \n(In thousands, except per share data)  \n(Unaudited)  \n**Three Months Ended** | **Nine Months Ended**  \n**September 28 ,2024** | **September 30 ,2023** | **September 28 ,2024** | **September 30 ,2023**  \nTotal revenues | $ | 11,581 | $ | 12,850 | $ | 35,973 | $ | 39,411  \nCost of revenues | 7,258 | 7,229 | 22,057 | 22,489  \nGross profit | 4,323 | 5,621 | 13,916 | 16,922  \nOperating expenses:  \nResearch and development | 1,299 | 1,541 | 4,336 | 5,135  \nSales and marketing | 2,646 | 3,823 | 9,879 | 12,370  \nGeneral and administrative | 2,248 | 1,945 | 7,501 | 6,343  \nTotal operating expenses | 6,193 | 7,309 | 21,716 | 23,848  \nLoss from operations | (1,870 | ) | (1,688 | ) | (7,800 | ) | (6,926 | )  \nOther income (expense), net | (46 | ) | (58 | ) | (202 | ) | 346  \nLoss from operations before provision for income taxes | (1,916 | ) | (1,746 | ) | (8,002 | ) | (6,580 | )  \nProvision for income taxes | 17 | 8 | 74 | 30  \nNet loss | $ | (1,933 | ) | $ | (1,754 | ) | $ | (8,076 | ) | $ | (6,610 | )  \nNet loss per share:  \nBasic | $ | (0.12 | ) | $ | (0.11 | ) | $ | (0.49 | ) | $ | (0.41 | )  \nDiluted | $ | (0.12 | ) | $ | (0.11 | ) | $ | (0.49 | ) | $ | (0.41 | )  \nWeighted average shares used in computing net loss per common share:  \nBasic | 16,581 | 16,231 | 16,374 | 16,089  \nDiluted | 16,581 | 16,231 | 16,374 | 16,089  \n**IRIDEX Corporation**  \n---  \n**Condensed Consolidated Balance Sheets**  \n(In thousands)  \n**September 28 ,2024** | **December 30 ,2023**  \n**ASSETS**  \nCurrent assets:  \nCash and cash equivalents | $ | 3,860 | $ | 7,034  \nAccounts receivable, net | 7,780 | 9,654  \nInventories | 10,942 | 9,906  \nPrepaid expenses and other current assets | 1,755 | 856  \nTotal current assets | 24,337 | 27,450  \nProperty and equipment, net | 157 | 351  \nIntangible assets, net | 1,391 | 1,642  \nGoodwill | 965 | 965  \nOperating lease right-of-use assets, net | 2,034 | 2,632  \nOther long-term assets | 1,270 | 1,396  \nTotal assets | $ | 30,154 | $ | 34,436  \n**LIABILITIES AND STOCKHOLDERS’ EQUITY**  \nCurrent liabilities:  \nAccounts payable | $ | 6,780 | $ | 4,727  \nAccrued compensation | 1,842 | 1,619  \nAccrued expenses | 1,007 | 1,996  \nConvertible note payable, current | 1,314 | —  \nOther current liabilities | 1,579 | 1,233  \nDeferred revenue, current | 2,335 | 2,404  \nOperating lease liabilities, current | 995 | 995  \nTotal current liabilities | 15,852 | 12,974  \nLong-term liabilities:  \nDeferred revenue | 8,759 | 10,025  \nOperating lease liabilities | 1,155 | 1,751  \nConvertible note payable | 1,444 | —  \nOther long-term liabilities | 321 | 164  \nTotal liabilities | 27,531 | 24,914  \nStockholders’ equity:  \nCommon stock | 174 | 172  \nAdditional paid-in capital | 89,565 | 88,444  \nAccumulated other comprehensive income (loss) | 2 | (52 | )  \nAccumulated deficit | (87,118 | ) | (79,042 | )  \nTotal stockholders’ equity | 2,623 | 9,522  \nTotal liabilities and stockholders’ equity | $ | 30,154 | $ | 34,436  \n![](https://www.globenewswire.com/newsroom/ti?nf=OTI3MjMzNyM2NTc5MDUwIzIwMDkxMDk=)![](https://ml.globenewswire.com/media/NjFiNDM4NTctMmM1Mi00YWNkLThjNDctZDFjMjNiMjQ3MDVkLTEwMjA2ODI=/tiny/IRIDEX-Corporation.png)\n\n[![Primary Logo](https://ml.globenewswire.com/media/2bb80159-a920-428b-aa69-c2f32e3038c9/small/iridex-corporate-logo-horizontal-rgb-m02-jpg.jpg)](https://www.globenewswire.com/NewsRoom/AttachmentNg/2bb80159-a920-428b-aa69-c2f32e3038c9)\n\nSource: IRIDEX Corporation  \n  \n##  Products\n\n[Lasers](http://www.iridex.com/Products/Lasers.aspx) [Delivery Devices](http://www.iridex.com/Products/DeliveryDevices.aspx) [Retina Consumables](http://www.iridex.com/Products/RetinaConsumables.aspx) [Glaucoma Device](http://www.iridex.com/Products/GlaucomaConsumables/G-Probe.aspx) | \n\n## Resources\n\n[Physician Information](http://www.iridex.com/PhysicianEducation.aspx) [Patient Information](http://www.iridex.com/PatientEducation.aspx) [Clinical Library](http://www.iridex.com/PhysicianEducation/ClinicalLibrary.aspx) | \n\n## About IRIDEX\n\n[Overview](http://www.iridex.com/Company/tabid/95/Default.aspx) [News](http://www.iridex.com/News.aspx) [Events](http://www.iridex.com/Events.aspx) [Contact Us](http://www.iridex.com/Contact.aspx) | \n\n## Company\n\n[Investors](/) [Offices/Contact](http://www.iridex.com/Contact/InternationalDistributors.aspx) [Careers](http://www.iridex.com/Company/Careers/tabid/96/Default.aspx)  \n---|---|---|---  \n[![twitter](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-twitter.jpg)](http://twitter.com/iridex) [![facebook](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-fb.jpg)](http://www.facebook.com/IRIDEX) [![linkedin](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-linkedin.jpg)](http://www.linkedin.com/company/iridex) [![youtuber](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-youtube.jpg)](http://www.youtube.com/user/IRIDEXCorp)  \n---  \n  \nCopyright 2024 by Iridex Corporation\n\n[Terms Of Use](http://www.iridex.com/terms.aspx) | [Privacy Statement](http://www.iridex.com/privacy.aspx)\n"
        },
        {
          "title": "Iridex to Report Third Quarter 2024 Financial Results on November 12, 2024",
          "url": "https://iridex.gcs-web.com/news-releases/news-release-details/iridex-report-third-quarter-2024-financial-results-november-12",
          "content": "[ Skip to main navigation ](#main-menu)\n\n![Iridex Logo](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/iridex-logo-tag.png)\n\n[Company](http://www.iridex.com/company.aspx) [Investors](/) [Find a Physician](http://www.iridex.com/fap) [News](https://iridex.gcs-web.com/news-releases?field_nir_news_date_value\\[min\\]=2020#views-exposed-form-widget-news-widget-news-ul) [Careers](https://iridex.com/careers.aspx) [Germany](http://www.iridex.de) [Search](http://www.iridex.com/IridexSearch.aspx)\n\nSales: 650-940-4700 \n\nSupport: (800) 388-4747 [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/facebook-top-icon.png)](http://www.facebook.com/IRIDEX) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/twitter-top-icon.png)](http://twitter.com/iridex) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/linkedin-top-icon.png)](http://www.linkedin.com/company/iridex) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/youtube-top-icon.png)](http://www.youtube.com/user/IRIDEXophthalmology) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/insta.jpg)](https://www.instagram.com/iridex_glaucoma)\n\n  * [Home](http://www.iridex.com/Default.aspx?tabid=56)\n  * [Products](http://www.iridex.com/Default.aspx?tabid=58)\n    * [Lasers](http://www.iridex.com/Default.aspx?tabid=102)\n      * [Cyclo G6](http://iridex.com/Products/Lasers/CYCLOG6MicroPulseP3.aspx)\n      * [IQ 532](https://iridex.com/Default.aspx?tabid=103)\n      * [IQ 577](https://iridex.com/Default.aspx?tabid=104)\n      * [OcuLight](https://iridex.com/Default.aspx?tabid=132)\n    * [Retina Delivery Devices](https://iridex.com/Default.aspx?tabid=107)\n      * [LIO](https://iridex.com/Default.aspx?tabid=384)\n      * [TxCell](https://iridex.com/Products/LaserDeliveryDevices/GlaucomaDevices/micropulsep3.aspx)\n    * [Glaucoma Devices](http://www.iridex.com/Default.aspx?tabid=184)\n      * [MicroPulse P3 Device](http://iridex.com/Products/Lasers/CYCLOG6MicroPulseP3.aspx)\n      * [Revised MicroPulse P3](https://iridex.com/Products/GlaucomaDevices/micropulsep3.aspx)\n      * [G-Probe](http://iridex.com/Default.aspx?tabid=112)\n      * [G-Probe Illuminate](http://iridex.com/Default.aspx?tabid=314)\n      * [MicroPulse Laser Trabeculoplasty (MLT) Lens](http://iridex.com/Default.aspx?tabid=178)\n    * [Retinal Surgical Instruments](http://iridex.com/Default.aspx?tabid=89)\n      * [Laser Probes](http://iridex.com/Default.aspx?tabid=208)\n      * [Consumables](http://iridex.com/Default.aspx?tabid=182)\n    * [Veterinary](http://www.iridex.com/Default.aspx?tabid=101)\n    * [ENT](http://www.iridex.com/Default.aspx?tabid=113)\n    * [Accessories](http://www.iridex.com/Default.aspx?tabid=350)\n      * [Vexio Cart](http://www.iridex.com/Default.aspx?tabid=351)\n  * [MicroPulse](http://www.iridex.com/Default.aspx?tabid=86)\n  * [Physician Education](http://www.iridex.com/Default.aspx?tabid=84)\n    * [Glaucoma](http://www.iridex.com/Default.aspx?tabid=158)\n      * [Library](http://www.iridex.com/Default.aspx?tabid=362)\n      * [MicroPulse P3 - CYCLO G6](http://www.iridex.com/Default.aspx?tabid=228)\n      * [TSCPC G-Probe](http://www.iridex.com/Default.aspx?tabid=120)\n      * [Trabeculoplasty (MLT)](http://www.iridex.com/Default.aspx?tabid=123)\n    * [Retina](http://www.iridex.com/Default.aspx?tabid=159)\n      * [Age-Related Macular Degeneration](http://www.iridex.com/Default.aspx?tabid=258)\n      * [Central Serous Chorioretinopathy](http://www.iridex.com/Default.aspx?tabid=149)\n      * [Diabetic Macular Edema ](http://www.iridex.com/Default.aspx?tabid=117)\n      * [ME due to RVOs](http://www.iridex.com/Default.aspx?tabid=161)\n      * [ROP](http://www.iridex.com/Default.aspx?tabid=202)\n      * [Vitreoretinal Surgery](http://www.iridex.com/Default.aspx?tabid=118)\n    * [Testimonials](http://www.iridex.com/Default.aspx?tabid=299)\n    * [Certification](http://www.iridex.com/Default.aspx?tabid=376)\n    * [Webinars](http://www.iridex.com/Default.aspx?tabid=288)\n    * [Seminars](http://www.iridex.com/Default.aspx?tabid=292)\n    * [Articles](http://www.iridex.com/Default.aspx?tabid=346)\n    * [Clinical Library](javascript:void\\(window.open\\('https://iridexsupport.zendesk.com/hc/en-us'\\)\\))\n    * [Reimbursement Calculator](http://www.iridex.com/Default.aspx?tabid=190)\n    * [Manuals](http://www.iridex.com/Default.aspx?tabid=385)\n  * [Patient Education](http://www.iridex.com/Default.aspx?tabid=85)\n    * [Treat My DME](javascript:void\\(window.open\\('http://treatmydme.com/'\\)\\))\n    * [Treat My Glaucoma](javascript:void\\(window.open\\('http://treatmyglaucoma.com/'\\)\\))\n    * [Find A Physician](http://www.iridex.com/Default.aspx?tabid=155)\n  * [Contact](http://www.iridex.com/Default.aspx?tabid=137)\n    * [Contact Us](http://www.iridex.com/Default.aspx?tabid=91)\n    * [Ask A Question](http://www.iridex.com/Default.aspx?tabid=92)\n    * [Schedule A Demo](http://www.iridex.com/Default.aspx?tabid=93)\n    * [Request A Quote](http://www.iridex.com/Default.aspx?tabid=94)\n    * [Order EndoProbe®](http://www.iridex.com/order-endoprobes/index.html)\n    * [International Distributors](http://www.iridex.com/Default.aspx?tabid=116)\n\n\n\n# Press Release\n\n<< [Back](#) Iridex to Report Third Quarter 2024 Financial Results on November 12, 2024 MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter 2024 and provide a business update after the close of trading on Tuesday, November 12, 2024. The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing 1-888-596-4144 for domestic callers or +1-646-968-2525 for international callers, using conference ID: 3650755. A live and recorded webcast on the “Event Calendar” page of the “Investors” section of the Company’s website at [www.iridex.com](http://www.iridex.com). **About Iridex Corporation ** Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at [www.iridex.com](http://www.iridex.com). MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2024 Iridex Corporation. All rights reserved. **Investor Relations Contact:** Philip TaylorGilmartin Group[investors@iridex.com](https://www.globenewswire.com/Tracker?data=7dOthGcFMT0nhGhTP0JUqFam7EdVrllWkPFBN4suS_xs-FPz2vPdGkSKcEMtFchzqCva7Hr56KgliT05OdR6lMNeG_oR5dF8pYVvPE4yX1o=)![](https://www.globenewswire.com/newsroom/ti?nf=OTI2NzA1NSM2NTY0MjUyIzIwMDkxMDk=)![](https://ml.globenewswire.com/media/ODVhYzdlZTMtNDg0MC00MTdhLTkxYzEtMDZjZjRjMTk4MWE1LTEwMjA2ODI=/tiny/IRIDEX-Corporation.png)[![Primary Logo](https://ml.globenewswire.com/media/2bb80159-a920-428b-aa69-c2f32e3038c9/small/iridex-corporate-logo-horizontal-rgb-m02-jpg.jpg)](https://www.globenewswire.com/NewsRoom/AttachmentNg/2bb80159-a920-428b-aa69-c2f32e3038c9) Source: IRIDEX Corporation  \n---  \n  \n##  Products\n\n[Lasers](http://www.iridex.com/Products/Lasers.aspx) [Delivery Devices](http://www.iridex.com/Products/DeliveryDevices.aspx) [Retina Consumables](http://www.iridex.com/Products/RetinaConsumables.aspx) [Glaucoma Device](http://www.iridex.com/Products/GlaucomaConsumables/G-Probe.aspx) | \n\n## Resources\n\n[Physician Information](http://www.iridex.com/PhysicianEducation.aspx) [Patient Information](http://www.iridex.com/PatientEducation.aspx) [Clinical Library](http://www.iridex.com/PhysicianEducation/ClinicalLibrary.aspx) | \n\n## About IRIDEX\n\n[Overview](http://www.iridex.com/Company/tabid/95/Default.aspx) [News](http://www.iridex.com/News.aspx) [Events](http://www.iridex.com/Events.aspx) [Contact Us](http://www.iridex.com/Contact.aspx) | \n\n## Company\n\n[Investors](/) [Offices/Contact](http://www.iridex.com/Contact/InternationalDistributors.aspx) [Careers](http://www.iridex.com/Company/Careers/tabid/96/Default.aspx)  \n---|---|---|---  \n[![twitter](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-twitter.jpg)](http://twitter.com/iridex) [![facebook](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-fb.jpg)](http://www.facebook.com/IRIDEX) [![linkedin](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-linkedin.jpg)](http://www.linkedin.com/company/iridex) [![youtuber](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-youtube.jpg)](http://www.youtube.com/user/IRIDEXCorp)  \n---  \n  \nCopyright 2024 by Iridex Corporation\n\n[Terms Of Use](http://www.iridex.com/terms.aspx) | [Privacy Statement](http://www.iridex.com/privacy.aspx)\n"
        },
        {
          "title": "Iridex Appoints Patrick Mercer as Chief Executive Officer",
          "url": "https://iridex.gcs-web.com/news-releases/news-release-details/iridex-appoints-patrick-mercer-chief-executive-officer",
          "content": "[ Skip to main navigation ](#main-menu)\n\n![Iridex Logo](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/iridex-logo-tag.png)\n\n[Company](http://www.iridex.com/company.aspx) [Investors](/) [Find a Physician](http://www.iridex.com/fap) [News](https://iridex.gcs-web.com/news-releases?field_nir_news_date_value\\[min\\]=2020#views-exposed-form-widget-news-widget-news-ul) [Careers](https://iridex.com/careers.aspx) [Germany](http://www.iridex.de) [Search](http://www.iridex.com/IridexSearch.aspx)\n\nSales: 650-940-4700 \n\nSupport: (800) 388-4747 [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/facebook-top-icon.png)](http://www.facebook.com/IRIDEX) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/twitter-top-icon.png)](http://twitter.com/iridex) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/linkedin-top-icon.png)](http://www.linkedin.com/company/iridex) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/youtube-top-icon.png)](http://www.youtube.com/user/IRIDEXophthalmology) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/insta.jpg)](https://www.instagram.com/iridex_glaucoma)\n\n  * [Home](http://www.iridex.com/Default.aspx?tabid=56)\n  * [Products](http://www.iridex.com/Default.aspx?tabid=58)\n    * [Lasers](http://www.iridex.com/Default.aspx?tabid=102)\n      * [Cyclo G6](http://iridex.com/Products/Lasers/CYCLOG6MicroPulseP3.aspx)\n      * [IQ 532](https://iridex.com/Default.aspx?tabid=103)\n      * [IQ 577](https://iridex.com/Default.aspx?tabid=104)\n      * [OcuLight](https://iridex.com/Default.aspx?tabid=132)\n    * [Retina Delivery Devices](https://iridex.com/Default.aspx?tabid=107)\n      * [LIO](https://iridex.com/Default.aspx?tabid=384)\n      * [TxCell](https://iridex.com/Products/LaserDeliveryDevices/GlaucomaDevices/micropulsep3.aspx)\n    * [Glaucoma Devices](http://www.iridex.com/Default.aspx?tabid=184)\n      * [MicroPulse P3 Device](http://iridex.com/Products/Lasers/CYCLOG6MicroPulseP3.aspx)\n      * [Revised MicroPulse P3](https://iridex.com/Products/GlaucomaDevices/micropulsep3.aspx)\n      * [G-Probe](http://iridex.com/Default.aspx?tabid=112)\n      * [G-Probe Illuminate](http://iridex.com/Default.aspx?tabid=314)\n      * [MicroPulse Laser Trabeculoplasty (MLT) Lens](http://iridex.com/Default.aspx?tabid=178)\n    * [Retinal Surgical Instruments](http://iridex.com/Default.aspx?tabid=89)\n      * [Laser Probes](http://iridex.com/Default.aspx?tabid=208)\n      * [Consumables](http://iridex.com/Default.aspx?tabid=182)\n    * [Veterinary](http://www.iridex.com/Default.aspx?tabid=101)\n    * [ENT](http://www.iridex.com/Default.aspx?tabid=113)\n    * [Accessories](http://www.iridex.com/Default.aspx?tabid=350)\n      * [Vexio Cart](http://www.iridex.com/Default.aspx?tabid=351)\n  * [MicroPulse](http://www.iridex.com/Default.aspx?tabid=86)\n  * [Physician Education](http://www.iridex.com/Default.aspx?tabid=84)\n    * [Glaucoma](http://www.iridex.com/Default.aspx?tabid=158)\n      * [Library](http://www.iridex.com/Default.aspx?tabid=362)\n      * [MicroPulse P3 - CYCLO G6](http://www.iridex.com/Default.aspx?tabid=228)\n      * [TSCPC G-Probe](http://www.iridex.com/Default.aspx?tabid=120)\n      * [Trabeculoplasty (MLT)](http://www.iridex.com/Default.aspx?tabid=123)\n    * [Retina](http://www.iridex.com/Default.aspx?tabid=159)\n      * [Age-Related Macular Degeneration](http://www.iridex.com/Default.aspx?tabid=258)\n      * [Central Serous Chorioretinopathy](http://www.iridex.com/Default.aspx?tabid=149)\n      * [Diabetic Macular Edema ](http://www.iridex.com/Default.aspx?tabid=117)\n      * [ME due to RVOs](http://www.iridex.com/Default.aspx?tabid=161)\n      * [ROP](http://www.iridex.com/Default.aspx?tabid=202)\n      * [Vitreoretinal Surgery](http://www.iridex.com/Default.aspx?tabid=118)\n    * [Testimonials](http://www.iridex.com/Default.aspx?tabid=299)\n    * [Certification](http://www.iridex.com/Default.aspx?tabid=376)\n    * [Webinars](http://www.iridex.com/Default.aspx?tabid=288)\n    * [Seminars](http://www.iridex.com/Default.aspx?tabid=292)\n    * [Articles](http://www.iridex.com/Default.aspx?tabid=346)\n    * [Clinical Library](javascript:void\\(window.open\\('https://iridexsupport.zendesk.com/hc/en-us'\\)\\))\n    * [Reimbursement Calculator](http://www.iridex.com/Default.aspx?tabid=190)\n    * [Manuals](http://www.iridex.com/Default.aspx?tabid=385)\n  * [Patient Education](http://www.iridex.com/Default.aspx?tabid=85)\n    * [Treat My DME](javascript:void\\(window.open\\('http://treatmydme.com/'\\)\\))\n    * [Treat My Glaucoma](javascript:void\\(window.open\\('http://treatmyglaucoma.com/'\\)\\))\n    * [Find A Physician](http://www.iridex.com/Default.aspx?tabid=155)\n  * [Contact](http://www.iridex.com/Default.aspx?tabid=137)\n    * [Contact Us](http://www.iridex.com/Default.aspx?tabid=91)\n    * [Ask A Question](http://www.iridex.com/Default.aspx?tabid=92)\n    * [Schedule A Demo](http://www.iridex.com/Default.aspx?tabid=93)\n    * [Request A Quote](http://www.iridex.com/Default.aspx?tabid=94)\n    * [Order EndoProbe®](http://www.iridex.com/order-endoprobes/index.html)\n    * [International Distributors](http://www.iridex.com/Default.aspx?tabid=116)\n\n\n\n# Press Release\n\n<< [Back](#) Iridex Appoints Patrick Mercer as Chief Executive Officer MOUNTAIN VIEW, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the appointment of Patrick Mercer as the Company’s Chief Executive Officer and President effective October 1, 2024. Previously Mr. Mercer served as the Company’s Chief Operating Officer and President. David Bruce, the Company’s prior Chief Executive Officer, is transitioning from the Company. Coincident to Mr. Mercer’s appointment, Scott Shuda was appointed Executive Chairman of the Company’s board of directors. Mr. Shuda had previously served as Chairman. “Iridex’s board of directors believes a change in leadership at this time has potential to accelerate progress toward a transaction under the strategic review process that the Company announced and initiated last year. The Company has and continues to be engaged in discussions with multiple entities relating to potential transactions,” commented Scott Shuda, Executive Chairman of the Iridex board of directors. Mr. Mercer added, “I am honored to assume the role of CEO at Iridex and lead our talented team as we continue to advance our mission of providing cutting-edge solutions for ophthalmic care. Iridex presents compelling value as a global leader in ophthalmic laser treatment systems, featuring industry-leading technology such as the Next Gen Pascal® with MicroPulse® for retina and MicroPulse Transscleral Laser Therapy for glaucoma. The Company’s management is aligned with the board of directors, and both are committed to completing the strategic review process and unlocking the value of these assets.” **About Iridex Corporation** Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at [www.iridex.com](https://www.globenewswire.com/Tracker?data=qA4V-lzSjtjAeWqrrOqCakHZzdSdvsYqonLGlgoiCcv7_h3dyriluIwR25o9nPwpUgMdTpANBkb-FGieSLPbIZWylchAPk_tK1BM1srSv5WnePPGydYUIPRiCgR_NbixBNGYJy4ZEQu3ZVYxRAIonj3ICpCSKVVFR4isTBlsVeELJkvpSIL4xyjVS_SGhLdA7PjVMeI3dhs9MZ57KXq1TaeBFh6wojgI6GLl3UoEwIPz-fb-kVMIitjtg2UsjJDxXPGf2TlCY01XU1E-3BPyQOHuHgsEbVmTC3748_V8HqEojoZyDkBW2apnXiN6gGaHbt_wVHZeu-bYC37XqwrU8H9vyBAICpUCaEwPjxVb0C0c4HZtZusjsRRjPHgd-HpT). MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2024 Iridex Corporation. All rights reserved. **Safe Harbor Statement** This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning pursuit of value-maximizing transactions and demand for and utilization of the Company's products. The Company can provide no assurance that it will complete any value-maximizing transactions on behalf of its stockholders. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2024. Forward-looking statements contained in this announcement are made as of this date and will not be updated. **Investor Relations Contact** Philip TaylorGilmartin Group[investors@iridex.com](https://www.globenewswire.com/Tracker?data=M5hnBM1TnnZISGwNaQ7G8QCzrszxj4n21HlEnYFCepoIOSqA44bTgx6PPzlaSPblL32qmBy5hs3p2fGoL7oUHtf7enWAWaS33q4HGqAOeL8=)![](https://www.globenewswire.com/newsroom/ti?nf=OTI1MTA3NSM2NTE4MzQ3IzIwMDkxMDk=)![](https://ml.globenewswire.com/media/NDRjNmYzOGQtYWIxZS00MzlkLWI5NzUtYWVlNWVjYTk2NjRkLTEwMjA2ODI=/tiny/IRIDEX-Corporation.png)[![Primary Logo](https://ml.globenewswire.com/media/2bb80159-a920-428b-aa69-c2f32e3038c9/small/iridex-corporate-logo-horizontal-rgb-m02-jpg.jpg)](https://www.globenewswire.com/NewsRoom/AttachmentNg/2bb80159-a920-428b-aa69-c2f32e3038c9) Source: IRIDEX Corporation  \n---  \n  \n##  Products\n\n[Lasers](http://www.iridex.com/Products/Lasers.aspx) [Delivery Devices](http://www.iridex.com/Products/DeliveryDevices.aspx) [Retina Consumables](http://www.iridex.com/Products/RetinaConsumables.aspx) [Glaucoma Device](http://www.iridex.com/Products/GlaucomaConsumables/G-Probe.aspx) | \n\n## Resources\n\n[Physician Information](http://www.iridex.com/PhysicianEducation.aspx) [Patient Information](http://www.iridex.com/PatientEducation.aspx) [Clinical Library](http://www.iridex.com/PhysicianEducation/ClinicalLibrary.aspx) | \n\n## About IRIDEX\n\n[Overview](http://www.iridex.com/Company/tabid/95/Default.aspx) [News](http://www.iridex.com/News.aspx) [Events](http://www.iridex.com/Events.aspx) [Contact Us](http://www.iridex.com/Contact.aspx) | \n\n## Company\n\n[Investors](/) [Offices/Contact](http://www.iridex.com/Contact/InternationalDistributors.aspx) [Careers](http://www.iridex.com/Company/Careers/tabid/96/Default.aspx)  \n---|---|---|---  \n[![twitter](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-twitter.jpg)](http://twitter.com/iridex) [![facebook](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-fb.jpg)](http://www.facebook.com/IRIDEX) [![linkedin](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-linkedin.jpg)](http://www.linkedin.com/company/iridex) [![youtuber](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-youtube.jpg)](http://www.youtube.com/user/IRIDEXCorp)  \n---  \n  \nCopyright 2024 by Iridex Corporation\n\n[Terms Of Use](http://www.iridex.com/terms.aspx) | [Privacy Statement](http://www.iridex.com/privacy.aspx)\n"
        }
      ]
    },
    {
      "section_name": "Financial Reports",
      "links": [
        {
          "title": "Quarterly Results",
          "url": "https://iridex.gcs-web.com/quarterly-results",
          "content": "[ Skip to main navigation ](#main-menu)\n\n![Iridex Logo](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/iridex-logo-tag.png)\n\n[Company](http://www.iridex.com/company.aspx) [Investors](/) [Find a Physician](http://www.iridex.com/fap) [News](https://iridex.gcs-web.com/news-releases?field_nir_news_date_value\\[min\\]=2020#views-exposed-form-widget-news-widget-news-ul) [Careers](https://iridex.com/careers.aspx) [Germany](http://www.iridex.de) [Search](http://www.iridex.com/IridexSearch.aspx)\n\nSales: 650-940-4700 \n\nSupport: (800) 388-4747 [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/facebook-top-icon.png)](http://www.facebook.com/IRIDEX) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/twitter-top-icon.png)](http://twitter.com/iridex) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/linkedin-top-icon.png)](http://www.linkedin.com/company/iridex) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/youtube-top-icon.png)](http://www.youtube.com/user/IRIDEXophthalmology) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/insta.jpg)](https://www.instagram.com/iridex_glaucoma)\n\n  * [Home](http://www.iridex.com/Default.aspx?tabid=56)\n  * [Products](http://www.iridex.com/Default.aspx?tabid=58)\n    * [Lasers](http://www.iridex.com/Default.aspx?tabid=102)\n      * [Cyclo G6](http://iridex.com/Products/Lasers/CYCLOG6MicroPulseP3.aspx)\n      * [IQ 532](https://iridex.com/Default.aspx?tabid=103)\n      * [IQ 577](https://iridex.com/Default.aspx?tabid=104)\n      * [OcuLight](https://iridex.com/Default.aspx?tabid=132)\n    * [Retina Delivery Devices](https://iridex.com/Default.aspx?tabid=107)\n      * [LIO](https://iridex.com/Default.aspx?tabid=384)\n      * [TxCell](https://iridex.com/Products/LaserDeliveryDevices/GlaucomaDevices/micropulsep3.aspx)\n    * [Glaucoma Devices](http://www.iridex.com/Default.aspx?tabid=184)\n      * [MicroPulse P3 Device](http://iridex.com/Products/Lasers/CYCLOG6MicroPulseP3.aspx)\n      * [Revised MicroPulse P3](https://iridex.com/Products/GlaucomaDevices/micropulsep3.aspx)\n      * [G-Probe](http://iridex.com/Default.aspx?tabid=112)\n      * [G-Probe Illuminate](http://iridex.com/Default.aspx?tabid=314)\n      * [MicroPulse Laser Trabeculoplasty (MLT) Lens](http://iridex.com/Default.aspx?tabid=178)\n    * [Retinal Surgical Instruments](http://iridex.com/Default.aspx?tabid=89)\n      * [Laser Probes](http://iridex.com/Default.aspx?tabid=208)\n      * [Consumables](http://iridex.com/Default.aspx?tabid=182)\n    * [Veterinary](http://www.iridex.com/Default.aspx?tabid=101)\n    * [ENT](http://www.iridex.com/Default.aspx?tabid=113)\n    * [Accessories](http://www.iridex.com/Default.aspx?tabid=350)\n      * [Vexio Cart](http://www.iridex.com/Default.aspx?tabid=351)\n  * [MicroPulse](http://www.iridex.com/Default.aspx?tabid=86)\n  * [Physician Education](http://www.iridex.com/Default.aspx?tabid=84)\n    * [Glaucoma](http://www.iridex.com/Default.aspx?tabid=158)\n      * [Library](http://www.iridex.com/Default.aspx?tabid=362)\n      * [MicroPulse P3 - CYCLO G6](http://www.iridex.com/Default.aspx?tabid=228)\n      * [TSCPC G-Probe](http://www.iridex.com/Default.aspx?tabid=120)\n      * [Trabeculoplasty (MLT)](http://www.iridex.com/Default.aspx?tabid=123)\n    * [Retina](http://www.iridex.com/Default.aspx?tabid=159)\n      * [Age-Related Macular Degeneration](http://www.iridex.com/Default.aspx?tabid=258)\n      * [Central Serous Chorioretinopathy](http://www.iridex.com/Default.aspx?tabid=149)\n      * [Diabetic Macular Edema ](http://www.iridex.com/Default.aspx?tabid=117)\n      * [ME due to RVOs](http://www.iridex.com/Default.aspx?tabid=161)\n      * [ROP](http://www.iridex.com/Default.aspx?tabid=202)\n      * [Vitreoretinal Surgery](http://www.iridex.com/Default.aspx?tabid=118)\n    * [Testimonials](http://www.iridex.com/Default.aspx?tabid=299)\n    * [Certification](http://www.iridex.com/Default.aspx?tabid=376)\n    * [Webinars](http://www.iridex.com/Default.aspx?tabid=288)\n    * [Seminars](http://www.iridex.com/Default.aspx?tabid=292)\n    * [Articles](http://www.iridex.com/Default.aspx?tabid=346)\n    * [Clinical Library](javascript:void\\(window.open\\('https://iridexsupport.zendesk.com/hc/en-us'\\)\\))\n    * [Reimbursement Calculator](http://www.iridex.com/Default.aspx?tabid=190)\n    * [Manuals](http://www.iridex.com/Default.aspx?tabid=385)\n  * [Patient Education](http://www.iridex.com/Default.aspx?tabid=85)\n    * [Treat My DME](javascript:void\\(window.open\\('http://treatmydme.com/'\\)\\))\n    * [Treat My Glaucoma](javascript:void\\(window.open\\('http://treatmyglaucoma.com/'\\)\\))\n    * [Find A Physician](http://www.iridex.com/Default.aspx?tabid=155)\n  * [Contact](http://www.iridex.com/Default.aspx?tabid=137)\n    * [Contact Us](http://www.iridex.com/Default.aspx?tabid=91)\n    * [Ask A Question](http://www.iridex.com/Default.aspx?tabid=92)\n    * [Schedule A Demo](http://www.iridex.com/Default.aspx?tabid=93)\n    * [Request A Quote](http://www.iridex.com/Default.aspx?tabid=94)\n    * [Order EndoProbe®](http://www.iridex.com/order-endoprobes/index.html)\n    * [International Distributors](http://www.iridex.com/Default.aspx?tabid=116)\n\n\n\n#  Quarterly Results \n\n[Show all](#)\n\n## 2024\n\nQ1\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-reports-first-quarter-2024-financial-results)\n  * [Webcast](/events/event-details/q1-2024-iridex-earnings-conference-call)\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0000950170-24-059771)\n\nQ2\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-reports-second-quarter-2024-financial-results)\n  * [Webcast](/events/event-details/q2-2024-iridex-earnings-conference-call)\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0000950170-24-094090)\n\nQ3\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-reports-third-quarter-2024-financial-results)\n  * [Webcast](/events/event-details/q3-2024-iridex-earnings-conference-call)\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0000950170-24-125541)\n\n\n\n## 2023\n\nQ1\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-reports-first-quarter-2023-financial-results)\n  * [Webcast](/events/event-details/q1-2023-iridex-earnings-conference-call)\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0000950170-23-021294)\n\nQ2\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-reports-second-quarter-2023-financial-results)\n  * [Webcast](/events/event-details/q2-2023-iridex-earnings-conference-call)\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0000950170-23-041376)\n\nQ3\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-reports-third-quarter-2023-financial-results-and-business)\n  * [Webcast](/events/event-details/q3-2023-iridex-earnings-conference-call)\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0000950170-23-065162)\n\nQ4\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-reports-fourth-quarter-and-full-year-2023-financial)\n  * [Webcast](/events/event-details/q4-2023-iridex-earnings-conference-call)\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0000950170-24-038650)\n\n\n\n## 2022\n\nQ1\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-announces-first-quarter-2022-financial-results)\n  * [Webcast](/events/event-details/q1-2022-iridex-earnings-conference-call)\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001564590-22-019891)\n\nQ2\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-announces-second-quarter-2022-financial-results)\n  * [Webcast](/events/event-details/q2-2022-iridex-earnings-conference-call)\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0000950170-22-017441)\n\nQ3\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-announces-record-third-quarter-2022-financial-results)\n  * [Webcast](/events/event-details/q3-2022-iridex-earnings-conference-call)\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0000950170-22-024520)\n\nQ4\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-reports-fourth-quarter-and-full-year-2022-financial)\n  * [Webcast](/events/event-details/q4-2022-iridex-earnings-conference-call)\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0000950170-23-007061)\n\n\n\n## 2021\n\nQ1\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-announces-first-quarter-2021-financial-results)\n  * [Webcast](/events/event-details/q1-2021-iridex-earnings-conference-call)\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001564590-21-026981)\n\nQ2\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-announces-second-quarter-2021-financial-results)\n  * [Webcast](/events/event-details/q2-2021-iridex-earnings-conference-call)\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001564590-21-044004)\n\nQ3\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-announces-third-quarter-2021-financial-results)\n  * [Webcast](/events/event-details/q3-2021-iridex-earnings-conference-call)\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001564590-21-056533)\n\nQ4\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-announces-fourth-quarter-and-full-year-2021-financial)\n  * [Webcast](/events/event-details/q4-2021-iridex-earnings-conference-call)\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001564590-22-010477)\n\n\n\n## 2020\n\nQ1\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-announces-first-quarter-2020-financial-results)\n  * [Webcast](/events/event-details/q1-2020-iridex-earnings-conference-call)\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001564590-20-024669)\n\nQ2\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-announces-second-quarter-2020-financial-results)\n  * [Webcast](/events/event-details/q2-2020-iridex-earnings-conference-call)\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001564590-20-038392)\n\nQ3\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-announces-third-quarter-2020-financial-results)\n  * [Webcast](/events/event-details/q3-2020-iridex-earnings-conference-call)\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001564590-20-052963)\n\nQ4\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-announces-fourth-quarter-and-full-year-2020-financial)\n  * [Webcast](/events/event-details/q4-2020-iridex-earnings-conference-call)\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001564590-21-014859)\n\n\n\n## 2019\n\nQ1\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-announces-2019-first-quarter-financial-results)\n  * [Webcast](/events/event-details/q1-2019-iridex-earnings-conference-call)\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001564590-19-016520)\n\nQ2\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-announces-2019-second-quarter-financial-results)\n  * [Webcast](/events/event-details/q2-2019-iridex-earnings-conference-call)\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001564590-19-030125)\n\nQ3\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-announces-2019-third-quarter-financial-results)\n  * [Webcast](/events/event-details/q3-2019-iridex-earnings-conference-call)\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001564590-19-042290)\n\nQ4\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-announces-fourth-quarter-and-full-year-2019-financial)\n  * [Webcast](/events/event-details/q4-2019-iridex-earnings-conference-call)\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001564590-20-010869)\n\n\n\n## 2018\n\nQ1\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-announces-2018-first-quarter-financial-results)\n  * [Webcast](/events/event-details/q1-2018-iridex-earnings-conference-call)\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001564590-18-011634)\n\nQ2\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-announces-2018-second-quarter-results-and-raises-full)\n  * [Webcast](/events/event-details/q2-2018-iridex-earnings-conference-call)\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001564590-18-020315)\n\nQ3\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-announces-2018-third-quarter-financial-results-and-raises)\n  * [Webcast](/events/event-details/q3-2018-iridex-earnings-conference-call)\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001564590-18-027454)\n\nQ4\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-announces-2018-fourth-quarter-and-full-year-financial)\n  * [Webcast](/events/event-details/q4-2018-iridex-earnings-conference-call)\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001564590-19-010196)\n\n\n\n## 2017\n\nQ1\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-announces-first-quarter-2017-financial-results)\n  * [Webcast](/events/event-details/q1-2017-iridex-earnings-conference-call)\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001564590-17-009920)\n\nQ2\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-announces-2017-second-quarter-six-month-financial-results)\n  * [Webcast](/events/event-details/q2-2017-iridex-earnings-conference-call)\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001564590-17-016430)\n\nQ3\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-announces-2017-third-quarter-financial-results)\n  * [Webcast](/events/event-details/q3-2017-iridex-earnings-conference-call)\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001564590-17-022136)\n\nQ4\n\n  * [Earnings Release](/news-releases/news-release-details/iridex-announces-2017-fourth-quarter-and-full-year-financial)\n  * [Webcast](/events/event-details/q4-2017-iridex-earnings-conference-call)\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001564590-18-005593)\n\n  \n---  \n  \n##  Products\n\n[Lasers](http://www.iridex.com/Products/Lasers.aspx) [Delivery Devices](http://www.iridex.com/Products/DeliveryDevices.aspx) [Retina Consumables](http://www.iridex.com/Products/RetinaConsumables.aspx) [Glaucoma Device](http://www.iridex.com/Products/GlaucomaConsumables/G-Probe.aspx) | \n\n## Resources\n\n[Physician Information](http://www.iridex.com/PhysicianEducation.aspx) [Patient Information](http://www.iridex.com/PatientEducation.aspx) [Clinical Library](http://www.iridex.com/PhysicianEducation/ClinicalLibrary.aspx) | \n\n## About IRIDEX\n\n[Overview](http://www.iridex.com/Company/tabid/95/Default.aspx) [News](http://www.iridex.com/News.aspx) [Events](http://www.iridex.com/Events.aspx) [Contact Us](http://www.iridex.com/Contact.aspx) | \n\n## Company\n\n[Investors](/) [Offices/Contact](http://www.iridex.com/Contact/InternationalDistributors.aspx) [Careers](http://www.iridex.com/Company/Careers/tabid/96/Default.aspx)  \n---|---|---|---  \n[![twitter](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-twitter.jpg)](http://twitter.com/iridex) [![facebook](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-fb.jpg)](http://www.facebook.com/IRIDEX) [![linkedin](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-linkedin.jpg)](http://www.linkedin.com/company/iridex) [![youtuber](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-youtube.jpg)](http://www.youtube.com/user/IRIDEXCorp)  \n---  \n  \nCopyright 2024 by Iridex Corporation\n\n[Terms Of Use](http://www.iridex.com/terms.aspx) | [Privacy Statement](http://www.iridex.com/privacy.aspx)\n"
        }
      ]
    },
    {
      "section_name": "Investor Relations",
      "links": [
        {
          "title": "Investor Relations Home",
          "url": "https://iridex.gcs-web.com/",
          "content": "[ Skip to main navigation ](#main-menu)\n\n![Iridex Logo](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/iridex-logo-tag.png)\n\n[Company](http://www.iridex.com/company.aspx) [Investors](/) [Find a Physician](http://www.iridex.com/fap) [News](https://iridex.gcs-web.com/news-releases?field_nir_news_date_value\\[min\\]=2020#views-exposed-form-widget-news-widget-news-ul) [Careers](https://iridex.com/careers.aspx) [Germany](http://www.iridex.de) [Search](http://www.iridex.com/IridexSearch.aspx)\n\nSales: 650-940-4700 \n\nSupport: (800) 388-4747 [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/facebook-top-icon.png)](http://www.facebook.com/IRIDEX) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/twitter-top-icon.png)](http://twitter.com/iridex) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/linkedin-top-icon.png)](http://www.linkedin.com/company/iridex) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/youtube-top-icon.png)](http://www.youtube.com/user/IRIDEXophthalmology) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/insta.jpg)](https://www.instagram.com/iridex_glaucoma)\n\n  * [Home](http://www.iridex.com/Default.aspx?tabid=56)\n  * [Products](http://www.iridex.com/Default.aspx?tabid=58)\n    * [Lasers](http://www.iridex.com/Default.aspx?tabid=102)\n      * [Cyclo G6](http://iridex.com/Products/Lasers/CYCLOG6MicroPulseP3.aspx)\n      * [IQ 532](https://iridex.com/Default.aspx?tabid=103)\n      * [IQ 577](https://iridex.com/Default.aspx?tabid=104)\n      * [OcuLight](https://iridex.com/Default.aspx?tabid=132)\n    * [Retina Delivery Devices](https://iridex.com/Default.aspx?tabid=107)\n      * [LIO](https://iridex.com/Default.aspx?tabid=384)\n      * [TxCell](https://iridex.com/Products/LaserDeliveryDevices/GlaucomaDevices/micropulsep3.aspx)\n    * [Glaucoma Devices](http://www.iridex.com/Default.aspx?tabid=184)\n      * [MicroPulse P3 Device](http://iridex.com/Products/Lasers/CYCLOG6MicroPulseP3.aspx)\n      * [Revised MicroPulse P3](https://iridex.com/Products/GlaucomaDevices/micropulsep3.aspx)\n      * [G-Probe](http://iridex.com/Default.aspx?tabid=112)\n      * [G-Probe Illuminate](http://iridex.com/Default.aspx?tabid=314)\n      * [MicroPulse Laser Trabeculoplasty (MLT) Lens](http://iridex.com/Default.aspx?tabid=178)\n    * [Retinal Surgical Instruments](http://iridex.com/Default.aspx?tabid=89)\n      * [Laser Probes](http://iridex.com/Default.aspx?tabid=208)\n      * [Consumables](http://iridex.com/Default.aspx?tabid=182)\n    * [Veterinary](http://www.iridex.com/Default.aspx?tabid=101)\n    * [ENT](http://www.iridex.com/Default.aspx?tabid=113)\n    * [Accessories](http://www.iridex.com/Default.aspx?tabid=350)\n      * [Vexio Cart](http://www.iridex.com/Default.aspx?tabid=351)\n  * [MicroPulse](http://www.iridex.com/Default.aspx?tabid=86)\n  * [Physician Education](http://www.iridex.com/Default.aspx?tabid=84)\n    * [Glaucoma](http://www.iridex.com/Default.aspx?tabid=158)\n      * [Library](http://www.iridex.com/Default.aspx?tabid=362)\n      * [MicroPulse P3 - CYCLO G6](http://www.iridex.com/Default.aspx?tabid=228)\n      * [TSCPC G-Probe](http://www.iridex.com/Default.aspx?tabid=120)\n      * [Trabeculoplasty (MLT)](http://www.iridex.com/Default.aspx?tabid=123)\n    * [Retina](http://www.iridex.com/Default.aspx?tabid=159)\n      * [Age-Related Macular Degeneration](http://www.iridex.com/Default.aspx?tabid=258)\n      * [Central Serous Chorioretinopathy](http://www.iridex.com/Default.aspx?tabid=149)\n      * [Diabetic Macular Edema ](http://www.iridex.com/Default.aspx?tabid=117)\n      * [ME due to RVOs](http://www.iridex.com/Default.aspx?tabid=161)\n      * [ROP](http://www.iridex.com/Default.aspx?tabid=202)\n      * [Vitreoretinal Surgery](http://www.iridex.com/Default.aspx?tabid=118)\n    * [Testimonials](http://www.iridex.com/Default.aspx?tabid=299)\n    * [Certification](http://www.iridex.com/Default.aspx?tabid=376)\n    * [Webinars](http://www.iridex.com/Default.aspx?tabid=288)\n    * [Seminars](http://www.iridex.com/Default.aspx?tabid=292)\n    * [Articles](http://www.iridex.com/Default.aspx?tabid=346)\n    * [Clinical Library](javascript:void\\(window.open\\('https://iridexsupport.zendesk.com/hc/en-us'\\)\\))\n    * [Reimbursement Calculator](http://www.iridex.com/Default.aspx?tabid=190)\n    * [Manuals](http://www.iridex.com/Default.aspx?tabid=385)\n  * [Patient Education](http://www.iridex.com/Default.aspx?tabid=85)\n    * [Treat My DME](javascript:void\\(window.open\\('http://treatmydme.com/'\\)\\))\n    * [Treat My Glaucoma](javascript:void\\(window.open\\('http://treatmyglaucoma.com/'\\)\\))\n    * [Find A Physician](http://www.iridex.com/Default.aspx?tabid=155)\n  * [Contact](http://www.iridex.com/Default.aspx?tabid=137)\n    * [Contact Us](http://www.iridex.com/Default.aspx?tabid=91)\n    * [Ask A Question](http://www.iridex.com/Default.aspx?tabid=92)\n    * [Schedule A Demo](http://www.iridex.com/Default.aspx?tabid=93)\n    * [Request A Quote](http://www.iridex.com/Default.aspx?tabid=94)\n    * [Order EndoProbe®](http://www.iridex.com/order-endoprobes/index.html)\n    * [International Distributors](http://www.iridex.com/Default.aspx?tabid=116)\n\n\n\n#  Investor Relations Home \n\n## Profile\n\nIRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries.\n\n## Stock Quote\n\n|  |  (Common Stock)   \n---  \nExchange |  (US Dollar)  \nPrice  \nChange (%)  \nVolume  \nData as of   \n  \nMinimum 15 minutes delayed. Source: LSEG\n\n## Recent News\n\nDate | Title | Teaser  \n---|---|---  \n11/19/24 |  [Summary Toggle](#)[Iridex Comments on Changing Glaucoma Reimbursement Landscape](/news-releases/news-release-details/iridex-comments-changing-glaucoma-reimbursement-landscape) |  MOUNTAIN VIEW, Calif. , Nov. 19, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today confirms that Local  |  [![](sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/toolkit_print_t.gif)](/news-releases/news-release-details/iridex-comments-changing-glaucoma-reimbursement-landscape)  \n11/12/24 |  [Summary Toggle](#)[Iridex Reports Third Quarter 2024 Financial Results](/news-releases/news-release-details/iridex-reports-third-quarter-2024-financial-results) |  MOUNTAIN VIEW, Calif. , Nov. 12, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results  |  [![](sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/toolkit_print_t.gif)](/news-releases/news-release-details/iridex-reports-third-quarter-2024-financial-results)  \n11/04/24 |  [Summary Toggle](#)[Iridex to Report Third Quarter 2024 Financial Results on November 12, 2024](/news-releases/news-release-details/iridex-report-third-quarter-2024-financial-results-november-12) |  MOUNTAIN VIEW, Calif. , Nov. 04, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will  |  [![](sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/toolkit_print_t.gif)](/news-releases/news-release-details/iridex-report-third-quarter-2024-financial-results-november-12)  \n10/03/24 |  [Summary Toggle](#)[Iridex Appoints Patrick Mercer as Chief Executive Officer](/news-releases/news-release-details/iridex-appoints-patrick-mercer-chief-executive-officer) |  MOUNTAIN VIEW, Calif. , Oct. 03, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the appointment  |  [![](sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/toolkit_print_t.gif)](/news-releases/news-release-details/iridex-appoints-patrick-mercer-chief-executive-officer)  \n  \n[Quarterly Results](https://iridex.gcs-web.com/quarterly-results)\n\n| Primary IR Contact  \n---  \nPhilip Trip Taylor Gilmartin Group 415-937-5406  \n  \n##  Products\n\n[Lasers](http://www.iridex.com/Products/Lasers.aspx) [Delivery Devices](http://www.iridex.com/Products/DeliveryDevices.aspx) [Retina Consumables](http://www.iridex.com/Products/RetinaConsumables.aspx) [Glaucoma Device](http://www.iridex.com/Products/GlaucomaConsumables/G-Probe.aspx) | \n\n## Resources\n\n[Physician Information](http://www.iridex.com/PhysicianEducation.aspx) [Patient Information](http://www.iridex.com/PatientEducation.aspx) [Clinical Library](http://www.iridex.com/PhysicianEducation/ClinicalLibrary.aspx) | \n\n## About IRIDEX\n\n[Overview](http://www.iridex.com/Company/tabid/95/Default.aspx) [News](http://www.iridex.com/News.aspx) [Events](http://www.iridex.com/Events.aspx) [Contact Us](http://www.iridex.com/Contact.aspx) | \n\n## Company\n\n[Investors](/) [Offices/Contact](http://www.iridex.com/Contact/InternationalDistributors.aspx) [Careers](http://www.iridex.com/Company/Careers/tabid/96/Default.aspx)  \n---|---|---|---  \n[![twitter](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-twitter.jpg)](http://twitter.com/iridex) [![facebook](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-fb.jpg)](http://www.facebook.com/IRIDEX) [![linkedin](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-linkedin.jpg)](http://www.linkedin.com/company/iridex) [![youtuber](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-youtube.jpg)](http://www.youtube.com/user/IRIDEXCorp)  \n---  \n  \nCopyright 2024 by Iridex Corporation\n\n[Terms Of Use](http://www.iridex.com/terms.aspx) | [Privacy Statement](http://www.iridex.com/privacy.aspx)\n"
        },
        {
          "title": "Stock Information",
          "url": "https://iridex.gcs-web.com/stock-information/stock-quote",
          "content": "[ Skip to main navigation ](#main-menu)\n\n![Iridex Logo](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/iridex-logo-tag.png)\n\n[Company](http://www.iridex.com/company.aspx) [Investors](/) [Find a Physician](http://www.iridex.com/fap) [News](https://iridex.gcs-web.com/news-releases?field_nir_news_date_value\\[min\\]=2020#views-exposed-form-widget-news-widget-news-ul) [Careers](https://iridex.com/careers.aspx) [Germany](http://www.iridex.de) [Search](http://www.iridex.com/IridexSearch.aspx)\n\nSales: 650-940-4700 \n\nSupport: (800) 388-4747 [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/facebook-top-icon.png)](http://www.facebook.com/IRIDEX) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/twitter-top-icon.png)](http://twitter.com/iridex) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/linkedin-top-icon.png)](http://www.linkedin.com/company/iridex) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/youtube-top-icon.png)](http://www.youtube.com/user/IRIDEXophthalmology) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/insta.jpg)](https://www.instagram.com/iridex_glaucoma)\n\n  * [Home](http://www.iridex.com/Default.aspx?tabid=56)\n  * [Products](http://www.iridex.com/Default.aspx?tabid=58)\n    * [Lasers](http://www.iridex.com/Default.aspx?tabid=102)\n      * [Cyclo G6](http://iridex.com/Products/Lasers/CYCLOG6MicroPulseP3.aspx)\n      * [IQ 532](https://iridex.com/Default.aspx?tabid=103)\n      * [IQ 577](https://iridex.com/Default.aspx?tabid=104)\n      * [OcuLight](https://iridex.com/Default.aspx?tabid=132)\n    * [Retina Delivery Devices](https://iridex.com/Default.aspx?tabid=107)\n      * [LIO](https://iridex.com/Default.aspx?tabid=384)\n      * [TxCell](https://iridex.com/Products/LaserDeliveryDevices/GlaucomaDevices/micropulsep3.aspx)\n    * [Glaucoma Devices](http://www.iridex.com/Default.aspx?tabid=184)\n      * [MicroPulse P3 Device](http://iridex.com/Products/Lasers/CYCLOG6MicroPulseP3.aspx)\n      * [Revised MicroPulse P3](https://iridex.com/Products/GlaucomaDevices/micropulsep3.aspx)\n      * [G-Probe](http://iridex.com/Default.aspx?tabid=112)\n      * [G-Probe Illuminate](http://iridex.com/Default.aspx?tabid=314)\n      * [MicroPulse Laser Trabeculoplasty (MLT) Lens](http://iridex.com/Default.aspx?tabid=178)\n    * [Retinal Surgical Instruments](http://iridex.com/Default.aspx?tabid=89)\n      * [Laser Probes](http://iridex.com/Default.aspx?tabid=208)\n      * [Consumables](http://iridex.com/Default.aspx?tabid=182)\n    * [Veterinary](http://www.iridex.com/Default.aspx?tabid=101)\n    * [ENT](http://www.iridex.com/Default.aspx?tabid=113)\n    * [Accessories](http://www.iridex.com/Default.aspx?tabid=350)\n      * [Vexio Cart](http://www.iridex.com/Default.aspx?tabid=351)\n  * [MicroPulse](http://www.iridex.com/Default.aspx?tabid=86)\n  * [Physician Education](http://www.iridex.com/Default.aspx?tabid=84)\n    * [Glaucoma](http://www.iridex.com/Default.aspx?tabid=158)\n      * [Library](http://www.iridex.com/Default.aspx?tabid=362)\n      * [MicroPulse P3 - CYCLO G6](http://www.iridex.com/Default.aspx?tabid=228)\n      * [TSCPC G-Probe](http://www.iridex.com/Default.aspx?tabid=120)\n      * [Trabeculoplasty (MLT)](http://www.iridex.com/Default.aspx?tabid=123)\n    * [Retina](http://www.iridex.com/Default.aspx?tabid=159)\n      * [Age-Related Macular Degeneration](http://www.iridex.com/Default.aspx?tabid=258)\n      * [Central Serous Chorioretinopathy](http://www.iridex.com/Default.aspx?tabid=149)\n      * [Diabetic Macular Edema ](http://www.iridex.com/Default.aspx?tabid=117)\n      * [ME due to RVOs](http://www.iridex.com/Default.aspx?tabid=161)\n      * [ROP](http://www.iridex.com/Default.aspx?tabid=202)\n      * [Vitreoretinal Surgery](http://www.iridex.com/Default.aspx?tabid=118)\n    * [Testimonials](http://www.iridex.com/Default.aspx?tabid=299)\n    * [Certification](http://www.iridex.com/Default.aspx?tabid=376)\n    * [Webinars](http://www.iridex.com/Default.aspx?tabid=288)\n    * [Seminars](http://www.iridex.com/Default.aspx?tabid=292)\n    * [Articles](http://www.iridex.com/Default.aspx?tabid=346)\n    * [Clinical Library](javascript:void\\(window.open\\('https://iridexsupport.zendesk.com/hc/en-us'\\)\\))\n    * [Reimbursement Calculator](http://www.iridex.com/Default.aspx?tabid=190)\n    * [Manuals](http://www.iridex.com/Default.aspx?tabid=385)\n  * [Patient Education](http://www.iridex.com/Default.aspx?tabid=85)\n    * [Treat My DME](javascript:void\\(window.open\\('http://treatmydme.com/'\\)\\))\n    * [Treat My Glaucoma](javascript:void\\(window.open\\('http://treatmyglaucoma.com/'\\)\\))\n    * [Find A Physician](http://www.iridex.com/Default.aspx?tabid=155)\n  * [Contact](http://www.iridex.com/Default.aspx?tabid=137)\n    * [Contact Us](http://www.iridex.com/Default.aspx?tabid=91)\n    * [Ask A Question](http://www.iridex.com/Default.aspx?tabid=92)\n    * [Schedule A Demo](http://www.iridex.com/Default.aspx?tabid=93)\n    * [Request A Quote](http://www.iridex.com/Default.aspx?tabid=94)\n    * [Order EndoProbe®](http://www.iridex.com/order-endoprobes/index.html)\n    * [International Distributors](http://www.iridex.com/Default.aspx?tabid=116)\n\n\n\n#  Stock Quote \n\n|  |  (Common Stock)   \n---  \nExchange |  (US Dollar)  \nPrice  \nChange (%)  \nVolume  \nToday's Open  \nPrevious Close  \nIntraday High  \nIntraday Low  \n52 Week High  \n52 Week Low  \nData as of   \n  \nMinimum 15 minutes delayed. Source: LSEG  \n  \n##  Products\n\n[Lasers](http://www.iridex.com/Products/Lasers.aspx) [Delivery Devices](http://www.iridex.com/Products/DeliveryDevices.aspx) [Retina Consumables](http://www.iridex.com/Products/RetinaConsumables.aspx) [Glaucoma Device](http://www.iridex.com/Products/GlaucomaConsumables/G-Probe.aspx) | \n\n## Resources\n\n[Physician Information](http://www.iridex.com/PhysicianEducation.aspx) [Patient Information](http://www.iridex.com/PatientEducation.aspx) [Clinical Library](http://www.iridex.com/PhysicianEducation/ClinicalLibrary.aspx) | \n\n## About IRIDEX\n\n[Overview](http://www.iridex.com/Company/tabid/95/Default.aspx) [News](http://www.iridex.com/News.aspx) [Events](http://www.iridex.com/Events.aspx) [Contact Us](http://www.iridex.com/Contact.aspx) | \n\n## Company\n\n[Investors](/) [Offices/Contact](http://www.iridex.com/Contact/InternationalDistributors.aspx) [Careers](http://www.iridex.com/Company/Careers/tabid/96/Default.aspx)  \n---|---|---|---  \n[![twitter](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-twitter.jpg)](http://twitter.com/iridex) [![facebook](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-fb.jpg)](http://www.facebook.com/IRIDEX) [![linkedin](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-linkedin.jpg)](http://www.linkedin.com/company/iridex) [![youtuber](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-youtube.jpg)](http://www.youtube.com/user/IRIDEXCorp)  \n---  \n  \nCopyright 2024 by Iridex Corporation\n\n[Terms Of Use](http://www.iridex.com/terms.aspx) | [Privacy Statement](http://www.iridex.com/privacy.aspx)\n"
        },
        {
          "title": "Analyst Coverage",
          "url": "https://iridex.gcs-web.com/stock-information/analyst-coverage",
          "content": "[ Skip to main navigation ](#main-menu)\n\n![Iridex Logo](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/iridex-logo-tag.png)\n\n[Company](http://www.iridex.com/company.aspx) [Investors](/) [Find a Physician](http://www.iridex.com/fap) [News](https://iridex.gcs-web.com/news-releases?field_nir_news_date_value\\[min\\]=2020#views-exposed-form-widget-news-widget-news-ul) [Careers](https://iridex.com/careers.aspx) [Germany](http://www.iridex.de) [Search](http://www.iridex.com/IridexSearch.aspx)\n\nSales: 650-940-4700 \n\nSupport: (800) 388-4747 [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/facebook-top-icon.png)](http://www.facebook.com/IRIDEX) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/twitter-top-icon.png)](http://twitter.com/iridex) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/linkedin-top-icon.png)](http://www.linkedin.com/company/iridex) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/youtube-top-icon.png)](http://www.youtube.com/user/IRIDEXophthalmology) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/insta.jpg)](https://www.instagram.com/iridex_glaucoma)\n\n  * [Home](http://www.iridex.com/Default.aspx?tabid=56)\n  * [Products](http://www.iridex.com/Default.aspx?tabid=58)\n    * [Lasers](http://www.iridex.com/Default.aspx?tabid=102)\n      * [Cyclo G6](http://iridex.com/Products/Lasers/CYCLOG6MicroPulseP3.aspx)\n      * [IQ 532](https://iridex.com/Default.aspx?tabid=103)\n      * [IQ 577](https://iridex.com/Default.aspx?tabid=104)\n      * [OcuLight](https://iridex.com/Default.aspx?tabid=132)\n    * [Retina Delivery Devices](https://iridex.com/Default.aspx?tabid=107)\n      * [LIO](https://iridex.com/Default.aspx?tabid=384)\n      * [TxCell](https://iridex.com/Products/LaserDeliveryDevices/GlaucomaDevices/micropulsep3.aspx)\n    * [Glaucoma Devices](http://www.iridex.com/Default.aspx?tabid=184)\n      * [MicroPulse P3 Device](http://iridex.com/Products/Lasers/CYCLOG6MicroPulseP3.aspx)\n      * [Revised MicroPulse P3](https://iridex.com/Products/GlaucomaDevices/micropulsep3.aspx)\n      * [G-Probe](http://iridex.com/Default.aspx?tabid=112)\n      * [G-Probe Illuminate](http://iridex.com/Default.aspx?tabid=314)\n      * [MicroPulse Laser Trabeculoplasty (MLT) Lens](http://iridex.com/Default.aspx?tabid=178)\n    * [Retinal Surgical Instruments](http://iridex.com/Default.aspx?tabid=89)\n      * [Laser Probes](http://iridex.com/Default.aspx?tabid=208)\n      * [Consumables](http://iridex.com/Default.aspx?tabid=182)\n    * [Veterinary](http://www.iridex.com/Default.aspx?tabid=101)\n    * [ENT](http://www.iridex.com/Default.aspx?tabid=113)\n    * [Accessories](http://www.iridex.com/Default.aspx?tabid=350)\n      * [Vexio Cart](http://www.iridex.com/Default.aspx?tabid=351)\n  * [MicroPulse](http://www.iridex.com/Default.aspx?tabid=86)\n  * [Physician Education](http://www.iridex.com/Default.aspx?tabid=84)\n    * [Glaucoma](http://www.iridex.com/Default.aspx?tabid=158)\n      * [Library](http://www.iridex.com/Default.aspx?tabid=362)\n      * [MicroPulse P3 - CYCLO G6](http://www.iridex.com/Default.aspx?tabid=228)\n      * [TSCPC G-Probe](http://www.iridex.com/Default.aspx?tabid=120)\n      * [Trabeculoplasty (MLT)](http://www.iridex.com/Default.aspx?tabid=123)\n    * [Retina](http://www.iridex.com/Default.aspx?tabid=159)\n      * [Age-Related Macular Degeneration](http://www.iridex.com/Default.aspx?tabid=258)\n      * [Central Serous Chorioretinopathy](http://www.iridex.com/Default.aspx?tabid=149)\n      * [Diabetic Macular Edema ](http://www.iridex.com/Default.aspx?tabid=117)\n      * [ME due to RVOs](http://www.iridex.com/Default.aspx?tabid=161)\n      * [ROP](http://www.iridex.com/Default.aspx?tabid=202)\n      * [Vitreoretinal Surgery](http://www.iridex.com/Default.aspx?tabid=118)\n    * [Testimonials](http://www.iridex.com/Default.aspx?tabid=299)\n    * [Certification](http://www.iridex.com/Default.aspx?tabid=376)\n    * [Webinars](http://www.iridex.com/Default.aspx?tabid=288)\n    * [Seminars](http://www.iridex.com/Default.aspx?tabid=292)\n    * [Articles](http://www.iridex.com/Default.aspx?tabid=346)\n    * [Clinical Library](javascript:void\\(window.open\\('https://iridexsupport.zendesk.com/hc/en-us'\\)\\))\n    * [Reimbursement Calculator](http://www.iridex.com/Default.aspx?tabid=190)\n    * [Manuals](http://www.iridex.com/Default.aspx?tabid=385)\n  * [Patient Education](http://www.iridex.com/Default.aspx?tabid=85)\n    * [Treat My DME](javascript:void\\(window.open\\('http://treatmydme.com/'\\)\\))\n    * [Treat My Glaucoma](javascript:void\\(window.open\\('http://treatmyglaucoma.com/'\\)\\))\n    * [Find A Physician](http://www.iridex.com/Default.aspx?tabid=155)\n  * [Contact](http://www.iridex.com/Default.aspx?tabid=137)\n    * [Contact Us](http://www.iridex.com/Default.aspx?tabid=91)\n    * [Ask A Question](http://www.iridex.com/Default.aspx?tabid=92)\n    * [Schedule A Demo](http://www.iridex.com/Default.aspx?tabid=93)\n    * [Request A Quote](http://www.iridex.com/Default.aspx?tabid=94)\n    * [Order EndoProbe®](http://www.iridex.com/order-endoprobes/index.html)\n    * [International Distributors](http://www.iridex.com/Default.aspx?tabid=116)\n\n\n\n#  Analyst Coverage \n\n| Firm | Analyst   \n---|---  \nStifel |  Tom Stephan   \n  \nIRIDEX is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding IRIDEX's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of IRIDEX or its management. IRIDEX does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.  \n  \n##  Products\n\n[Lasers](http://www.iridex.com/Products/Lasers.aspx) [Delivery Devices](http://www.iridex.com/Products/DeliveryDevices.aspx) [Retina Consumables](http://www.iridex.com/Products/RetinaConsumables.aspx) [Glaucoma Device](http://www.iridex.com/Products/GlaucomaConsumables/G-Probe.aspx) | \n\n## Resources\n\n[Physician Information](http://www.iridex.com/PhysicianEducation.aspx) [Patient Information](http://www.iridex.com/PatientEducation.aspx) [Clinical Library](http://www.iridex.com/PhysicianEducation/ClinicalLibrary.aspx) | \n\n## About IRIDEX\n\n[Overview](http://www.iridex.com/Company/tabid/95/Default.aspx) [News](http://www.iridex.com/News.aspx) [Events](http://www.iridex.com/Events.aspx) [Contact Us](http://www.iridex.com/Contact.aspx) | \n\n## Company\n\n[Investors](/) [Offices/Contact](http://www.iridex.com/Contact/InternationalDistributors.aspx) [Careers](http://www.iridex.com/Company/Careers/tabid/96/Default.aspx)  \n---|---|---|---  \n[![twitter](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-twitter.jpg)](http://twitter.com/iridex) [![facebook](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-fb.jpg)](http://www.facebook.com/IRIDEX) [![linkedin](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-linkedin.jpg)](http://www.linkedin.com/company/iridex) [![youtuber](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-youtube.jpg)](http://www.youtube.com/user/IRIDEXCorp)  \n---  \n  \nCopyright 2024 by Iridex Corporation\n\n[Terms Of Use](http://www.iridex.com/terms.aspx) | [Privacy Statement](http://www.iridex.com/privacy.aspx)\n"
        },
        {
          "title": "Corporate Governance",
          "url": "https://iridex.gcs-web.com/corporate-governance-highlights",
          "content": "[ Skip to main navigation ](#main-menu)\n\n![Iridex Logo](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/iridex-logo-tag.png)\n\n[Company](http://www.iridex.com/company.aspx) [Investors](/) [Find a Physician](http://www.iridex.com/fap) [News](https://iridex.gcs-web.com/news-releases?field_nir_news_date_value\\[min\\]=2020#views-exposed-form-widget-news-widget-news-ul) [Careers](https://iridex.com/careers.aspx) [Germany](http://www.iridex.de) [Search](http://www.iridex.com/IridexSearch.aspx)\n\nSales: 650-940-4700 \n\nSupport: (800) 388-4747 [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/facebook-top-icon.png)](http://www.facebook.com/IRIDEX) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/twitter-top-icon.png)](http://twitter.com/iridex) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/linkedin-top-icon.png)](http://www.linkedin.com/company/iridex) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/youtube-top-icon.png)](http://www.youtube.com/user/IRIDEXophthalmology) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/insta.jpg)](https://www.instagram.com/iridex_glaucoma)\n\n  * [Home](http://www.iridex.com/Default.aspx?tabid=56)\n  * [Products](http://www.iridex.com/Default.aspx?tabid=58)\n    * [Lasers](http://www.iridex.com/Default.aspx?tabid=102)\n      * [Cyclo G6](http://iridex.com/Products/Lasers/CYCLOG6MicroPulseP3.aspx)\n      * [IQ 532](https://iridex.com/Default.aspx?tabid=103)\n      * [IQ 577](https://iridex.com/Default.aspx?tabid=104)\n      * [OcuLight](https://iridex.com/Default.aspx?tabid=132)\n    * [Retina Delivery Devices](https://iridex.com/Default.aspx?tabid=107)\n      * [LIO](https://iridex.com/Default.aspx?tabid=384)\n      * [TxCell](https://iridex.com/Products/LaserDeliveryDevices/GlaucomaDevices/micropulsep3.aspx)\n    * [Glaucoma Devices](http://www.iridex.com/Default.aspx?tabid=184)\n      * [MicroPulse P3 Device](http://iridex.com/Products/Lasers/CYCLOG6MicroPulseP3.aspx)\n      * [Revised MicroPulse P3](https://iridex.com/Products/GlaucomaDevices/micropulsep3.aspx)\n      * [G-Probe](http://iridex.com/Default.aspx?tabid=112)\n      * [G-Probe Illuminate](http://iridex.com/Default.aspx?tabid=314)\n      * [MicroPulse Laser Trabeculoplasty (MLT) Lens](http://iridex.com/Default.aspx?tabid=178)\n    * [Retinal Surgical Instruments](http://iridex.com/Default.aspx?tabid=89)\n      * [Laser Probes](http://iridex.com/Default.aspx?tabid=208)\n      * [Consumables](http://iridex.com/Default.aspx?tabid=182)\n    * [Veterinary](http://www.iridex.com/Default.aspx?tabid=101)\n    * [ENT](http://www.iridex.com/Default.aspx?tabid=113)\n    * [Accessories](http://www.iridex.com/Default.aspx?tabid=350)\n      * [Vexio Cart](http://www.iridex.com/Default.aspx?tabid=351)\n  * [MicroPulse](http://www.iridex.com/Default.aspx?tabid=86)\n  * [Physician Education](http://www.iridex.com/Default.aspx?tabid=84)\n    * [Glaucoma](http://www.iridex.com/Default.aspx?tabid=158)\n      * [Library](http://www.iridex.com/Default.aspx?tabid=362)\n      * [MicroPulse P3 - CYCLO G6](http://www.iridex.com/Default.aspx?tabid=228)\n      * [TSCPC G-Probe](http://www.iridex.com/Default.aspx?tabid=120)\n      * [Trabeculoplasty (MLT)](http://www.iridex.com/Default.aspx?tabid=123)\n    * [Retina](http://www.iridex.com/Default.aspx?tabid=159)\n      * [Age-Related Macular Degeneration](http://www.iridex.com/Default.aspx?tabid=258)\n      * [Central Serous Chorioretinopathy](http://www.iridex.com/Default.aspx?tabid=149)\n      * [Diabetic Macular Edema ](http://www.iridex.com/Default.aspx?tabid=117)\n      * [ME due to RVOs](http://www.iridex.com/Default.aspx?tabid=161)\n      * [ROP](http://www.iridex.com/Default.aspx?tabid=202)\n      * [Vitreoretinal Surgery](http://www.iridex.com/Default.aspx?tabid=118)\n    * [Testimonials](http://www.iridex.com/Default.aspx?tabid=299)\n    * [Certification](http://www.iridex.com/Default.aspx?tabid=376)\n    * [Webinars](http://www.iridex.com/Default.aspx?tabid=288)\n    * [Seminars](http://www.iridex.com/Default.aspx?tabid=292)\n    * [Articles](http://www.iridex.com/Default.aspx?tabid=346)\n    * [Clinical Library](javascript:void\\(window.open\\('https://iridexsupport.zendesk.com/hc/en-us'\\)\\))\n    * [Reimbursement Calculator](http://www.iridex.com/Default.aspx?tabid=190)\n    * [Manuals](http://www.iridex.com/Default.aspx?tabid=385)\n  * [Patient Education](http://www.iridex.com/Default.aspx?tabid=85)\n    * [Treat My DME](javascript:void\\(window.open\\('http://treatmydme.com/'\\)\\))\n    * [Treat My Glaucoma](javascript:void\\(window.open\\('http://treatmyglaucoma.com/'\\)\\))\n    * [Find A Physician](http://www.iridex.com/Default.aspx?tabid=155)\n  * [Contact](http://www.iridex.com/Default.aspx?tabid=137)\n    * [Contact Us](http://www.iridex.com/Default.aspx?tabid=91)\n    * [Ask A Question](http://www.iridex.com/Default.aspx?tabid=92)\n    * [Schedule A Demo](http://www.iridex.com/Default.aspx?tabid=93)\n    * [Request A Quote](http://www.iridex.com/Default.aspx?tabid=94)\n    * [Order EndoProbe®](http://www.iridex.com/order-endoprobes/index.html)\n    * [International Distributors](http://www.iridex.com/Default.aspx?tabid=116)\n\n\n\n#  Corporate Governance - Highlights \n\nIRIDEX Corporation is committed to maintaining high standards of financial integrity, and the Audit and Corporate Governance Committee of the IRIDEX Board of Directors takes very seriously all complaints and concerns regarding accounting, internal accounting controls and auditing matters. IRIDEX strives to encourage open communication so that such concerns may be raised without fear of retaliation in any manner. Accordingly, individuals may submit concerns regarding accounting, internal accounting controls, or auditing matters they believe to be questionable (confidentially and anonymously, if desired) in one of the following ways: Via Internet to Ethicspoint, Inc., an independent third party service provider, at [www.ethicspoint.com](http://www.ethicspoint.com) or Via telephone hotline to Ethicspoint at 1-866-ETHICSP (1-866-384-4277). \n\n## Committee Charters\n\n| \n\n  * Add Files [Audit Committee](/static-files/8eb5714a-10c5-431b-a986-c3f233cbfe55 \"Audit Committee Charter - revised May 2020_palib2_10480927.\\(1\\).pdf\") 191.3 KB\n\n  \n---  \n  \n  * Add Files [Compensation Committee](/static-files/59f438c4-08df-41ef-b3fe-b62f1560ad64 \"finalMarch9_20 comp commcharterIRIX.pdf\") 161.1 KB\n\n  \n  \n  * Add Files [Nominating and Governance Committee](/static-files/cde24317-1a0d-45c8-9b29-85f07782bfcd \"Iridex - Nominating and Governance Committee Charter \\(Final 2020\\)_palib2_10451615.\\(1\\).pdf\") 144 KB\n\n  \n  \n## Governance Documents\n\n  * Add Files [Complaint Procedures for Accounting and Auditing Matters](/static-files/b69677de-7329-4835-8e60-0a02d2011276 \"complaint_procedures.pdf\") 109 KB\n\n  \n---  \n  \n  * Add Files [Charter for the Role of Chairman of the Board](/static-files/cd1d3853-05ce-4af0-9b03-a2107c94eb2e \"Charter_Roll_of_the_Chairman - Oct 2019.pdf\") 82.5 KB\n\n  \n  \n  * Add Files [Board Governance Guidelines ](/static-files/b070c38e-50ce-40c5-b69c-a6697a111320 \"Iridex - Board Governance Guidelines \\(WS 3-10-20\\)_palib2_10365840.\\(1\\).pdf\") 185.1 KB\n\n  \n  \n  * Add Files [Code of Business Conduct and Ethics](/static-files/4d1200fd-3995-4419-afa7-672660849655 \"IRIDEX Code of Conduct \\(Updated 10252017\\).pdf\") 114.3 KB\n\n  \n  \n  * Add Files [Supply Chain Policy and Supplier Guidelines](/static-files/2d4863d9-fe45-4a4a-b451-4817fbf0e08f \"IRIDEX Supply Chain Policy and Supplier Guidelines.pdf\") 45.8 KB\n\n  \n  \n  * Add Files [Conflict Minerals Report](/static-files/1478019d-84b9-4985-b9db-285023a68c4a \"SD for IR.pdf\") 457.2 KB\n\n  \n  \n##  Products\n\n[Lasers](http://www.iridex.com/Products/Lasers.aspx) [Delivery Devices](http://www.iridex.com/Products/DeliveryDevices.aspx) [Retina Consumables](http://www.iridex.com/Products/RetinaConsumables.aspx) [Glaucoma Device](http://www.iridex.com/Products/GlaucomaConsumables/G-Probe.aspx) | \n\n## Resources\n\n[Physician Information](http://www.iridex.com/PhysicianEducation.aspx) [Patient Information](http://www.iridex.com/PatientEducation.aspx) [Clinical Library](http://www.iridex.com/PhysicianEducation/ClinicalLibrary.aspx) | \n\n## About IRIDEX\n\n[Overview](http://www.iridex.com/Company/tabid/95/Default.aspx) [News](http://www.iridex.com/News.aspx) [Events](http://www.iridex.com/Events.aspx) [Contact Us](http://www.iridex.com/Contact.aspx) | \n\n## Company\n\n[Investors](/) [Offices/Contact](http://www.iridex.com/Contact/InternationalDistributors.aspx) [Careers](http://www.iridex.com/Company/Careers/tabid/96/Default.aspx)  \n---|---|---|---  \n[![twitter](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-twitter.jpg)](http://twitter.com/iridex) [![facebook](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-fb.jpg)](http://www.facebook.com/IRIDEX) [![linkedin](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-linkedin.jpg)](http://www.linkedin.com/company/iridex) [![youtuber](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-youtube.jpg)](http://www.youtube.com/user/IRIDEXCorp)  \n---  \n  \nCopyright 2024 by Iridex Corporation\n\n[Terms Of Use](http://www.iridex.com/terms.aspx) | [Privacy Statement](http://www.iridex.com/privacy.aspx)\n"
        },
        {
          "title": "SEC Filings",
          "url": "https://iridex.gcs-web.com/financial-information/sec-filings",
          "content": "[ Skip to main navigation ](#main-menu)\n\n![Iridex Logo](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/iridex-logo-tag.png)\n\n[Company](http://www.iridex.com/company.aspx) [Investors](/) [Find a Physician](http://www.iridex.com/fap) [News](https://iridex.gcs-web.com/news-releases?field_nir_news_date_value\\[min\\]=2020#views-exposed-form-widget-news-widget-news-ul) [Careers](https://iridex.com/careers.aspx) [Germany](http://www.iridex.de) [Search](http://www.iridex.com/IridexSearch.aspx)\n\nSales: 650-940-4700 \n\nSupport: (800) 388-4747 [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/facebook-top-icon.png)](http://www.facebook.com/IRIDEX) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/twitter-top-icon.png)](http://twitter.com/iridex) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/linkedin-top-icon.png)](http://www.linkedin.com/company/iridex) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/youtube-top-icon.png)](http://www.youtube.com/user/IRIDEXophthalmology) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/insta.jpg)](https://www.instagram.com/iridex_glaucoma)\n\n  * [Home](http://www.iridex.com/Default.aspx?tabid=56)\n  * [Products](http://www.iridex.com/Default.aspx?tabid=58)\n    * [Lasers](http://www.iridex.com/Default.aspx?tabid=102)\n      * [Cyclo G6](http://iridex.com/Products/Lasers/CYCLOG6MicroPulseP3.aspx)\n      * [IQ 532](https://iridex.com/Default.aspx?tabid=103)\n      * [IQ 577](https://iridex.com/Default.aspx?tabid=104)\n      * [OcuLight](https://iridex.com/Default.aspx?tabid=132)\n    * [Retina Delivery Devices](https://iridex.com/Default.aspx?tabid=107)\n      * [LIO](https://iridex.com/Default.aspx?tabid=384)\n      * [TxCell](https://iridex.com/Products/LaserDeliveryDevices/GlaucomaDevices/micropulsep3.aspx)\n    * [Glaucoma Devices](http://www.iridex.com/Default.aspx?tabid=184)\n      * [MicroPulse P3 Device](http://iridex.com/Products/Lasers/CYCLOG6MicroPulseP3.aspx)\n      * [Revised MicroPulse P3](https://iridex.com/Products/GlaucomaDevices/micropulsep3.aspx)\n      * [G-Probe](http://iridex.com/Default.aspx?tabid=112)\n      * [G-Probe Illuminate](http://iridex.com/Default.aspx?tabid=314)\n      * [MicroPulse Laser Trabeculoplasty (MLT) Lens](http://iridex.com/Default.aspx?tabid=178)\n    * [Retinal Surgical Instruments](http://iridex.com/Default.aspx?tabid=89)\n      * [Laser Probes](http://iridex.com/Default.aspx?tabid=208)\n      * [Consumables](http://iridex.com/Default.aspx?tabid=182)\n    * [Veterinary](http://www.iridex.com/Default.aspx?tabid=101)\n    * [ENT](http://www.iridex.com/Default.aspx?tabid=113)\n    * [Accessories](http://www.iridex.com/Default.aspx?tabid=350)\n      * [Vexio Cart](http://www.iridex.com/Default.aspx?tabid=351)\n  * [MicroPulse](http://www.iridex.com/Default.aspx?tabid=86)\n  * [Physician Education](http://www.iridex.com/Default.aspx?tabid=84)\n    * [Glaucoma](http://www.iridex.com/Default.aspx?tabid=158)\n      * [Library](http://www.iridex.com/Default.aspx?tabid=362)\n      * [MicroPulse P3 - CYCLO G6](http://www.iridex.com/Default.aspx?tabid=228)\n      * [TSCPC G-Probe](http://www.iridex.com/Default.aspx?tabid=120)\n      * [Trabeculoplasty (MLT)](http://www.iridex.com/Default.aspx?tabid=123)\n    * [Retina](http://www.iridex.com/Default.aspx?tabid=159)\n      * [Age-Related Macular Degeneration](http://www.iridex.com/Default.aspx?tabid=258)\n      * [Central Serous Chorioretinopathy](http://www.iridex.com/Default.aspx?tabid=149)\n      * [Diabetic Macular Edema ](http://www.iridex.com/Default.aspx?tabid=117)\n      * [ME due to RVOs](http://www.iridex.com/Default.aspx?tabid=161)\n      * [ROP](http://www.iridex.com/Default.aspx?tabid=202)\n      * [Vitreoretinal Surgery](http://www.iridex.com/Default.aspx?tabid=118)\n    * [Testimonials](http://www.iridex.com/Default.aspx?tabid=299)\n    * [Certification](http://www.iridex.com/Default.aspx?tabid=376)\n    * [Webinars](http://www.iridex.com/Default.aspx?tabid=288)\n    * [Seminars](http://www.iridex.com/Default.aspx?tabid=292)\n    * [Articles](http://www.iridex.com/Default.aspx?tabid=346)\n    * [Clinical Library](javascript:void\\(window.open\\('https://iridexsupport.zendesk.com/hc/en-us'\\)\\))\n    * [Reimbursement Calculator](http://www.iridex.com/Default.aspx?tabid=190)\n    * [Manuals](http://www.iridex.com/Default.aspx?tabid=385)\n  * [Patient Education](http://www.iridex.com/Default.aspx?tabid=85)\n    * [Treat My DME](javascript:void\\(window.open\\('http://treatmydme.com/'\\)\\))\n    * [Treat My Glaucoma](javascript:void\\(window.open\\('http://treatmyglaucoma.com/'\\)\\))\n    * [Find A Physician](http://www.iridex.com/Default.aspx?tabid=155)\n  * [Contact](http://www.iridex.com/Default.aspx?tabid=137)\n    * [Contact Us](http://www.iridex.com/Default.aspx?tabid=91)\n    * [Ask A Question](http://www.iridex.com/Default.aspx?tabid=92)\n    * [Schedule A Demo](http://www.iridex.com/Default.aspx?tabid=93)\n    * [Request A Quote](http://www.iridex.com/Default.aspx?tabid=94)\n    * [Order EndoProbe®](http://www.iridex.com/order-endoprobes/index.html)\n    * [International Distributors](http://www.iridex.com/Default.aspx?tabid=116)\n\n\n\n#  SEC Filings \n\n## SEC Filing Keyword Search\n\nGroup 3,4,5Annual FilingsCurrent ReportsMergers & AcquisitionsOtherProxy FilingsQuarterly FilingsRegistration Statements Filing year - Any -20242023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996- Any - | [Filing date ](?items_per_page=10&order=field_nir_sec_date_filed&sort=asc \"sort by Filing date\") | [Form](?items_per_page=10&order=field_nir_sec_form&sort=asc \"sort by Form\") | [Description](?items_per_page=10&order=field_nir_sec_description&sort=asc \"sort by Description\") | Filing Group | View  \n---|---|---|---|---  \n11/26/24 | [8-K](/sec-filings/sec-filing/8-k/0000950170-24-130698) | Report of unscheduled material events or corporate event |  Current Reports |  [0000950170-24-130698.pdf](/static-files/8b023512-dc26-451b-ba46-21534e2a548f) [0000950170-24-130698.rtf](/static-files/d5e537c8-e206-4488-800a-917292da537e) [0000950170-24-130698.xls](/static-files/c7122f79-de6f-47b1-816f-6084bd0bf05b) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0000950170-24-130698)  \n11/26/24 | [8-K/A](/sec-filings/sec-filing/8-ka/0000950170-24-130699) | Amendment to a previously filed 8-K |  Current Reports |  [0000950170-24-130699.pdf](/static-files/03f28ada-0bca-434b-b085-d1c57103c7b8) [0000950170-24-130699.rtf](/static-files/a502e1ee-8d78-42bf-9dd3-003c009d638a) [0000950170-24-130699.xls](/static-files/38b19b08-ca4f-431d-a662-35031fb787d7) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-ka/0000950170-24-130699)  \n11/13/24 | [8-K](/sec-filings/sec-filing/8-k/0000950170-24-126507) | Report of unscheduled material events or corporate event |  Current Reports |  [0000950170-24-126507.pdf](/static-files/67379abc-8104-4a7b-974f-7080a4960cbf) [0000950170-24-126507.rtf](/static-files/e64aa8b4-3064-44e9-8481-9f21c0b7d29a) [0000950170-24-126507.xls](/static-files/0d626638-1771-4c77-a2c3-82ae3a15465c) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0000950170-24-126507)  \n11/12/24 | [8-K](/sec-filings/sec-filing/8-k/0000950170-24-125464) | Report of unscheduled material events or corporate event |  Current Reports |  [0000950170-24-125464.pdf](/static-files/71f0de61-a16e-4c38-8aa2-546dffca5159) [0000950170-24-125464.rtf](/static-files/2243955f-a6a3-491e-873e-7f79c9dccf19) [0000950170-24-125464.xls](/static-files/2cf2d123-9d2f-4bc7-aef1-e2258e8f67df) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0000950170-24-125464)  \n11/12/24 | [10-Q](/sec-filings/sec-filing/10-q/0000950170-24-125541) | Quarterly report which provides a continuing view of a company's financial position |  Quarterly Filings |  [0000950170-24-125541.pdf](/static-files/6e6f5741-aa8a-4037-9f87-4702a92833a4) [0000950170-24-125541.rtf](/static-files/168962df-0bc6-4b5c-8f76-4d287336c41d) [0000950170-24-125541.xls](/static-files/21b67659-dcd1-4f61-aa43-886827bb9259) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-q/0000950170-24-125541)  \n11/08/24 | [4](/sec-filings/sec-filing/4/0000950170-24-124321) | Statement of changes in beneficial ownership of securities |  3,4,5 |  [0000950170-24-124321.pdf](/static-files/5d033eb0-837f-4d3d-bfee-b68c6944ae46) [0000950170-24-124321.rtf](/static-files/cf5fa81d-e2ec-4c29-9617-685b59e26fc8) [0000950170-24-124321.xls](/static-files/ff6759af-e5ed-418d-88ff-b2bbeddbe13e)  \n10/03/24 | [8-K](/sec-filings/sec-filing/8-k/0000950170-24-112474) | Report of unscheduled material events or corporate event |  Current Reports |  [0000950170-24-112474.pdf](/static-files/bce9118d-5666-4bf1-ade1-06ca6299b2a2) [0000950170-24-112474.rtf](/static-files/0843e3ad-8771-456a-94bf-ecee0b07f385) [0000950170-24-112474.xls](/static-files/5f908070-bdb3-420c-8939-51639dc246f7) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0000950170-24-112474)  \n09/25/24 | [424B3](/sec-filings/sec-filing/424b3/0000950170-24-109332) | Form of prospectus reflecting facts events constituting substantive change from last form |  Registration Statements |  [0000950170-24-109332.pdf](/static-files/c2bb0c04-8d7a-4bfc-b66f-7c527176f3ed) [0000950170-24-109332.rtf](/static-files/7687b5e8-6bb1-4e5e-b012-19724982ee8d) [0000950170-24-109332.xls](/static-files/35471f71-8b0a-4c5d-b989-a1e2fe092468)  \n09/24/24 | [EFFECT](/sec-filings/sec-filing/effect/9999999995-24-002946) | EFFECT |  Other |  [9999999995-24-002946.pdf](/static-files/29a155bc-2414-4383-8f30-445c7c28aa61) [9999999995-24-002946.rtf](/static-files/92608220-f179-4986-92b9-cfd4a70468b5) [9999999995-24-002946.xls](/static-files/e026771d-2def-4171-a688-5da0c9546998)  \n09/20/24 | [CORRESP](/sec-filings/sec-filing/corresp/0000950170-24-108379) | CORRESP |  Other |  [0000950170-24-108379.pdf](/static-files/2dc6de10-c29b-44db-a162-75e58dd1916e) [0000950170-24-108379.rtf](/static-files/c48379d4-6278-4068-9808-e1f5adc3b124)  \n  \nData provided by [Kaleidoscope](https://www.kscope.io).  \n  \n##  Products\n\n[Lasers](http://www.iridex.com/Products/Lasers.aspx) [Delivery Devices](http://www.iridex.com/Products/DeliveryDevices.aspx) [Retina Consumables](http://www.iridex.com/Products/RetinaConsumables.aspx) [Glaucoma Device](http://www.iridex.com/Products/GlaucomaConsumables/G-Probe.aspx) | \n\n## Resources\n\n[Physician Information](http://www.iridex.com/PhysicianEducation.aspx) [Patient Information](http://www.iridex.com/PatientEducation.aspx) [Clinical Library](http://www.iridex.com/PhysicianEducation/ClinicalLibrary.aspx) | \n\n## About IRIDEX\n\n[Overview](http://www.iridex.com/Company/tabid/95/Default.aspx) [News](http://www.iridex.com/News.aspx) [Events](http://www.iridex.com/Events.aspx) [Contact Us](http://www.iridex.com/Contact.aspx) | \n\n## Company\n\n[Investors](/) [Offices/Contact](http://www.iridex.com/Contact/InternationalDistributors.aspx) [Careers](http://www.iridex.com/Company/Careers/tabid/96/Default.aspx)  \n---|---|---|---  \n[![twitter](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-twitter.jpg)](http://twitter.com/iridex) [![facebook](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-fb.jpg)](http://www.facebook.com/IRIDEX) [![linkedin](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-linkedin.jpg)](http://www.linkedin.com/company/iridex) [![youtuber](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-youtube.jpg)](http://www.youtube.com/user/IRIDEXCorp)  \n---  \n  \nCopyright 2024 by Iridex Corporation\n\n[Terms Of Use](http://www.iridex.com/terms.aspx) | [Privacy Statement](http://www.iridex.com/privacy.aspx)\n"
        },
        {
          "title": "Email Alerts",
          "url": "https://iridex.gcs-web.com/shareholder-services/email-alerts",
          "content": "[ Skip to main navigation ](#main-menu)\n\n![Iridex Logo](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/iridex-logo-tag.png)\n\n[Company](http://www.iridex.com/company.aspx) [Investors](/) [Find a Physician](http://www.iridex.com/fap) [News](https://iridex.gcs-web.com/news-releases?field_nir_news_date_value\\[min\\]=2020#views-exposed-form-widget-news-widget-news-ul) [Careers](https://iridex.com/careers.aspx) [Germany](http://www.iridex.de) [Search](http://www.iridex.com/IridexSearch.aspx)\n\nSales: 650-940-4700 \n\nSupport: (800) 388-4747 [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/facebook-top-icon.png)](http://www.facebook.com/IRIDEX) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/twitter-top-icon.png)](http://twitter.com/iridex) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/linkedin-top-icon.png)](http://www.linkedin.com/company/iridex) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/youtube-top-icon.png)](http://www.youtube.com/user/IRIDEXophthalmology) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/insta.jpg)](https://www.instagram.com/iridex_glaucoma)\n\n  * [Home](http://www.iridex.com/Default.aspx?tabid=56)\n  * [Products](http://www.iridex.com/Default.aspx?tabid=58)\n    * [Lasers](http://www.iridex.com/Default.aspx?tabid=102)\n      * [Cyclo G6](http://iridex.com/Products/Lasers/CYCLOG6MicroPulseP3.aspx)\n      * [IQ 532](https://iridex.com/Default.aspx?tabid=103)\n      * [IQ 577](https://iridex.com/Default.aspx?tabid=104)\n      * [OcuLight](https://iridex.com/Default.aspx?tabid=132)\n    * [Retina Delivery Devices](https://iridex.com/Default.aspx?tabid=107)\n      * [LIO](https://iridex.com/Default.aspx?tabid=384)\n      * [TxCell](https://iridex.com/Products/LaserDeliveryDevices/GlaucomaDevices/micropulsep3.aspx)\n    * [Glaucoma Devices](http://www.iridex.com/Default.aspx?tabid=184)\n      * [MicroPulse P3 Device](http://iridex.com/Products/Lasers/CYCLOG6MicroPulseP3.aspx)\n      * [Revised MicroPulse P3](https://iridex.com/Products/GlaucomaDevices/micropulsep3.aspx)\n      * [G-Probe](http://iridex.com/Default.aspx?tabid=112)\n      * [G-Probe Illuminate](http://iridex.com/Default.aspx?tabid=314)\n      * [MicroPulse Laser Trabeculoplasty (MLT) Lens](http://iridex.com/Default.aspx?tabid=178)\n    * [Retinal Surgical Instruments](http://iridex.com/Default.aspx?tabid=89)\n      * [Laser Probes](http://iridex.com/Default.aspx?tabid=208)\n      * [Consumables](http://iridex.com/Default.aspx?tabid=182)\n    * [Veterinary](http://www.iridex.com/Default.aspx?tabid=101)\n    * [ENT](http://www.iridex.com/Default.aspx?tabid=113)\n    * [Accessories](http://www.iridex.com/Default.aspx?tabid=350)\n      * [Vexio Cart](http://www.iridex.com/Default.aspx?tabid=351)\n  * [MicroPulse](http://www.iridex.com/Default.aspx?tabid=86)\n  * [Physician Education](http://www.iridex.com/Default.aspx?tabid=84)\n    * [Glaucoma](http://www.iridex.com/Default.aspx?tabid=158)\n      * [Library](http://www.iridex.com/Default.aspx?tabid=362)\n      * [MicroPulse P3 - CYCLO G6](http://www.iridex.com/Default.aspx?tabid=228)\n      * [TSCPC G-Probe](http://www.iridex.com/Default.aspx?tabid=120)\n      * [Trabeculoplasty (MLT)](http://www.iridex.com/Default.aspx?tabid=123)\n    * [Retina](http://www.iridex.com/Default.aspx?tabid=159)\n      * [Age-Related Macular Degeneration](http://www.iridex.com/Default.aspx?tabid=258)\n      * [Central Serous Chorioretinopathy](http://www.iridex.com/Default.aspx?tabid=149)\n      * [Diabetic Macular Edema ](http://www.iridex.com/Default.aspx?tabid=117)\n      * [ME due to RVOs](http://www.iridex.com/Default.aspx?tabid=161)\n      * [ROP](http://www.iridex.com/Default.aspx?tabid=202)\n      * [Vitreoretinal Surgery](http://www.iridex.com/Default.aspx?tabid=118)\n    * [Testimonials](http://www.iridex.com/Default.aspx?tabid=299)\n    * [Certification](http://www.iridex.com/Default.aspx?tabid=376)\n    * [Webinars](http://www.iridex.com/Default.aspx?tabid=288)\n    * [Seminars](http://www.iridex.com/Default.aspx?tabid=292)\n    * [Articles](http://www.iridex.com/Default.aspx?tabid=346)\n    * [Clinical Library](javascript:void\\(window.open\\('https://iridexsupport.zendesk.com/hc/en-us'\\)\\))\n    * [Reimbursement Calculator](http://www.iridex.com/Default.aspx?tabid=190)\n    * [Manuals](http://www.iridex.com/Default.aspx?tabid=385)\n  * [Patient Education](http://www.iridex.com/Default.aspx?tabid=85)\n    * [Treat My DME](javascript:void\\(window.open\\('http://treatmydme.com/'\\)\\))\n    * [Treat My Glaucoma](javascript:void\\(window.open\\('http://treatmyglaucoma.com/'\\)\\))\n    * [Find A Physician](http://www.iridex.com/Default.aspx?tabid=155)\n  * [Contact](http://www.iridex.com/Default.aspx?tabid=137)\n    * [Contact Us](http://www.iridex.com/Default.aspx?tabid=91)\n    * [Ask A Question](http://www.iridex.com/Default.aspx?tabid=92)\n    * [Schedule A Demo](http://www.iridex.com/Default.aspx?tabid=93)\n    * [Request A Quote](http://www.iridex.com/Default.aspx?tabid=94)\n    * [Order EndoProbe®](http://www.iridex.com/order-endoprobes/index.html)\n    * [International Distributors](http://www.iridex.com/Default.aspx?tabid=116)\n\n\n\n#  E-mail Alerts \n\n| You may automatically receive IRIDEX financial information by e-mail. To choose your options for e-mail notification, please enter your e-mail address below and click Submit.  \n---  \n  \nRequired fields denoted by an asterisk ().\n\nHide lower priority columns\n\nAlert type  \n---  \nIRIDEX End-of-Day Stock Quote Alert  \nIRIDEX SEC Alert  \nIRIDEX Events Alert  \nIRIDEX Press Release Alert  \nIRIDEX Presentation Alert  \nIRIDEX Report Alert  \n  \nEmail\n\nLeave this field blank  \n  \n##  Products\n\n[Lasers](http://www.iridex.com/Products/Lasers.aspx) [Delivery Devices](http://www.iridex.com/Products/DeliveryDevices.aspx) [Retina Consumables](http://www.iridex.com/Products/RetinaConsumables.aspx) [Glaucoma Device](http://www.iridex.com/Products/GlaucomaConsumables/G-Probe.aspx) | \n\n## Resources\n\n[Physician Information](http://www.iridex.com/PhysicianEducation.aspx) [Patient Information](http://www.iridex.com/PatientEducation.aspx) [Clinical Library](http://www.iridex.com/PhysicianEducation/ClinicalLibrary.aspx) | \n\n## About IRIDEX\n\n[Overview](http://www.iridex.com/Company/tabid/95/Default.aspx) [News](http://www.iridex.com/News.aspx) [Events](http://www.iridex.com/Events.aspx) [Contact Us](http://www.iridex.com/Contact.aspx) | \n\n## Company\n\n[Investors](/) [Offices/Contact](http://www.iridex.com/Contact/InternationalDistributors.aspx) [Careers](http://www.iridex.com/Company/Careers/tabid/96/Default.aspx)  \n---|---|---|---  \n[![twitter](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-twitter.jpg)](http://twitter.com/iridex) [![facebook](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-fb.jpg)](http://www.facebook.com/IRIDEX) [![linkedin](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-linkedin.jpg)](http://www.linkedin.com/company/iridex) [![youtuber](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-youtube.jpg)](http://www.youtube.com/user/IRIDEXCorp)  \n---  \n  \nCopyright 2024 by Iridex Corporation\n\n[Terms Of Use](http://www.iridex.com/terms.aspx) | [Privacy Statement](http://www.iridex.com/privacy.aspx)\n"
        },
        {
          "title": "Information Request",
          "url": "https://iridex.gcs-web.com/shareholder-services/document-request",
          "content": "[ Skip to main navigation ](#main-menu)\n\n![Iridex Logo](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/iridex-logo-tag.png)\n\n[Company](http://www.iridex.com/company.aspx) [Investors](/) [Find a Physician](http://www.iridex.com/fap) [News](https://iridex.gcs-web.com/news-releases?field_nir_news_date_value\\[min\\]=2020#views-exposed-form-widget-news-widget-news-ul) [Careers](https://iridex.com/careers.aspx) [Germany](http://www.iridex.de) [Search](http://www.iridex.com/IridexSearch.aspx)\n\nSales: 650-940-4700 \n\nSupport: (800) 388-4747 [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/facebook-top-icon.png)](http://www.facebook.com/IRIDEX) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/twitter-top-icon.png)](http://twitter.com/iridex) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/linkedin-top-icon.png)](http://www.linkedin.com/company/iridex) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/youtube-top-icon.png)](http://www.youtube.com/user/IRIDEXophthalmology) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/insta.jpg)](https://www.instagram.com/iridex_glaucoma)\n\n  * [Home](http://www.iridex.com/Default.aspx?tabid=56)\n  * [Products](http://www.iridex.com/Default.aspx?tabid=58)\n    * [Lasers](http://www.iridex.com/Default.aspx?tabid=102)\n      * [Cyclo G6](http://iridex.com/Products/Lasers/CYCLOG6MicroPulseP3.aspx)\n      * [IQ 532](https://iridex.com/Default.aspx?tabid=103)\n      * [IQ 577](https://iridex.com/Default.aspx?tabid=104)\n      * [OcuLight](https://iridex.com/Default.aspx?tabid=132)\n    * [Retina Delivery Devices](https://iridex.com/Default.aspx?tabid=107)\n      * [LIO](https://iridex.com/Default.aspx?tabid=384)\n      * [TxCell](https://iridex.com/Products/LaserDeliveryDevices/GlaucomaDevices/micropulsep3.aspx)\n    * [Glaucoma Devices](http://www.iridex.com/Default.aspx?tabid=184)\n      * [MicroPulse P3 Device](http://iridex.com/Products/Lasers/CYCLOG6MicroPulseP3.aspx)\n      * [Revised MicroPulse P3](https://iridex.com/Products/GlaucomaDevices/micropulsep3.aspx)\n      * [G-Probe](http://iridex.com/Default.aspx?tabid=112)\n      * [G-Probe Illuminate](http://iridex.com/Default.aspx?tabid=314)\n      * [MicroPulse Laser Trabeculoplasty (MLT) Lens](http://iridex.com/Default.aspx?tabid=178)\n    * [Retinal Surgical Instruments](http://iridex.com/Default.aspx?tabid=89)\n      * [Laser Probes](http://iridex.com/Default.aspx?tabid=208)\n      * [Consumables](http://iridex.com/Default.aspx?tabid=182)\n    * [Veterinary](http://www.iridex.com/Default.aspx?tabid=101)\n    * [ENT](http://www.iridex.com/Default.aspx?tabid=113)\n    * [Accessories](http://www.iridex.com/Default.aspx?tabid=350)\n      * [Vexio Cart](http://www.iridex.com/Default.aspx?tabid=351)\n  * [MicroPulse](http://www.iridex.com/Default.aspx?tabid=86)\n  * [Physician Education](http://www.iridex.com/Default.aspx?tabid=84)\n    * [Glaucoma](http://www.iridex.com/Default.aspx?tabid=158)\n      * [Library](http://www.iridex.com/Default.aspx?tabid=362)\n      * [MicroPulse P3 - CYCLO G6](http://www.iridex.com/Default.aspx?tabid=228)\n      * [TSCPC G-Probe](http://www.iridex.com/Default.aspx?tabid=120)\n      * [Trabeculoplasty (MLT)](http://www.iridex.com/Default.aspx?tabid=123)\n    * [Retina](http://www.iridex.com/Default.aspx?tabid=159)\n      * [Age-Related Macular Degeneration](http://www.iridex.com/Default.aspx?tabid=258)\n      * [Central Serous Chorioretinopathy](http://www.iridex.com/Default.aspx?tabid=149)\n      * [Diabetic Macular Edema ](http://www.iridex.com/Default.aspx?tabid=117)\n      * [ME due to RVOs](http://www.iridex.com/Default.aspx?tabid=161)\n      * [ROP](http://www.iridex.com/Default.aspx?tabid=202)\n      * [Vitreoretinal Surgery](http://www.iridex.com/Default.aspx?tabid=118)\n    * [Testimonials](http://www.iridex.com/Default.aspx?tabid=299)\n    * [Certification](http://www.iridex.com/Default.aspx?tabid=376)\n    * [Webinars](http://www.iridex.com/Default.aspx?tabid=288)\n    * [Seminars](http://www.iridex.com/Default.aspx?tabid=292)\n    * [Articles](http://www.iridex.com/Default.aspx?tabid=346)\n    * [Clinical Library](javascript:void\\(window.open\\('https://iridexsupport.zendesk.com/hc/en-us'\\)\\))\n    * [Reimbursement Calculator](http://www.iridex.com/Default.aspx?tabid=190)\n    * [Manuals](http://www.iridex.com/Default.aspx?tabid=385)\n  * [Patient Education](http://www.iridex.com/Default.aspx?tabid=85)\n    * [Treat My DME](javascript:void\\(window.open\\('http://treatmydme.com/'\\)\\))\n    * [Treat My Glaucoma](javascript:void\\(window.open\\('http://treatmyglaucoma.com/'\\)\\))\n    * [Find A Physician](http://www.iridex.com/Default.aspx?tabid=155)\n  * [Contact](http://www.iridex.com/Default.aspx?tabid=137)\n    * [Contact Us](http://www.iridex.com/Default.aspx?tabid=91)\n    * [Ask A Question](http://www.iridex.com/Default.aspx?tabid=92)\n    * [Schedule A Demo](http://www.iridex.com/Default.aspx?tabid=93)\n    * [Request A Quote](http://www.iridex.com/Default.aspx?tabid=94)\n    * [Order EndoProbe®](http://www.iridex.com/order-endoprobes/index.html)\n    * [International Distributors](http://www.iridex.com/Default.aspx?tabid=116)\n\n\n\n#  Information Request \n\nTo request information via mail, please fill out and submit the form below: Personal Information Required fields denoted by an asterisk (*). Material Selections 10-Q Annual Report Product Information First Name Last Name Email Title Company Investor Type - None -Individual InvestorBuy-Side AnalystSell-Side AnalystPortfolio ManagerStock BrokerEmployeeNews MediaLibraryOther- None - Address Country - None -AfghanistanÅland IslandsAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua & BarbudaArgentinaArmeniaArubaAscension IslandAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBosnia & HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBritish Virgin IslandsBruneiBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCanary IslandsCape VerdeCaribbean NetherlandsCayman IslandsCentral African RepublicCeuta & MelillaChadChileChinaChristmas IslandClipperton IslandCocos (Keeling) IslandsColombiaComorosCongo - BrazzavilleCongo - KinshasaCook IslandsCosta RicaCôte d’IvoireCroatiaCubaCuraçaoCyprusCzechiaDenmarkDiego GarciaDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard & McDonald IslandsHondurasHong Kong SAR ChinaHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKosovoKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacao SAR ChinaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmar (Burma)NamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth KoreaNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestinian TerritoriesPanamaPapua New GuineaParaguayPeruPhilippinesPitcairn IslandsPolandPortugalPuerto RicoQatarRéunionRomaniaRussiaRwandaSamoaSan MarinoSão Tomé & PríncipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia & South Sandwich IslandsSouth KoreaSouth SudanSpainSri LankaSt. BarthélemySt. HelenaSt. Kitts & NevisSt. LuciaSt. MartinSt. Pierre & MiquelonSt. Vincent & GrenadinesSudanSurinameSvalbard & Jan MayenSwedenSwitzerlandSyriaTaiwanTajikistanTanzaniaThailandTimor-LesteTogoTokelauTongaTrinidad & TobagoTristan da CunhaTunisiaTurkeyTurkmenistanTurks & Caicos IslandsTuvaluU.S. Outlying IslandsU.S. Virgin IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVatican CityVenezuelaVietnamWallis & FutunaWestern SaharaYemenZambiaZimbabwe- None - Work Phone Fax Home Phone Comments Leave this field blank  \n---  \n  \n##  Products\n\n[Lasers](http://www.iridex.com/Products/Lasers.aspx) [Delivery Devices](http://www.iridex.com/Products/DeliveryDevices.aspx) [Retina Consumables](http://www.iridex.com/Products/RetinaConsumables.aspx) [Glaucoma Device](http://www.iridex.com/Products/GlaucomaConsumables/G-Probe.aspx) | \n\n## Resources\n\n[Physician Information](http://www.iridex.com/PhysicianEducation.aspx) [Patient Information](http://www.iridex.com/PatientEducation.aspx) [Clinical Library](http://www.iridex.com/PhysicianEducation/ClinicalLibrary.aspx) | \n\n## About IRIDEX\n\n[Overview](http://www.iridex.com/Company/tabid/95/Default.aspx) [News](http://www.iridex.com/News.aspx) [Events](http://www.iridex.com/Events.aspx) [Contact Us](http://www.iridex.com/Contact.aspx) | \n\n## Company\n\n[Investors](/) [Offices/Contact](http://www.iridex.com/Contact/InternationalDistributors.aspx) [Careers](http://www.iridex.com/Company/Careers/tabid/96/Default.aspx)  \n---|---|---|---  \n[![twitter](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-twitter.jpg)](http://twitter.com/iridex) [![facebook](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-fb.jpg)](http://www.facebook.com/IRIDEX) [![linkedin](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-linkedin.jpg)](http://www.linkedin.com/company/iridex) [![youtuber](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-youtube.jpg)](http://www.youtube.com/user/IRIDEXCorp)  \n---  \n  \nCopyright 2024 by Iridex Corporation\n\n[Terms Of Use](http://www.iridex.com/terms.aspx) | [Privacy Statement](http://www.iridex.com/privacy.aspx)\n"
        },
        {
          "title": "Proxy Online",
          "url": "https://iridex.gcs-web.com/proxy",
          "content": "[ Skip to main navigation ](#main-menu)\n\n![Iridex Logo](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/iridex-logo-tag.png)\n\n[Company](http://www.iridex.com/company.aspx) [Investors](/) [Find a Physician](http://www.iridex.com/fap) [News](https://iridex.gcs-web.com/news-releases?field_nir_news_date_value\\[min\\]=2020#views-exposed-form-widget-news-widget-news-ul) [Careers](https://iridex.com/careers.aspx) [Germany](http://www.iridex.de) [Search](http://www.iridex.com/IridexSearch.aspx)\n\nSales: 650-940-4700 \n\nSupport: (800) 388-4747 [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/facebook-top-icon.png)](http://www.facebook.com/IRIDEX) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/twitter-top-icon.png)](http://twitter.com/iridex) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/linkedin-top-icon.png)](http://www.linkedin.com/company/iridex) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/youtube-top-icon.png)](http://www.youtube.com/user/IRIDEXophthalmology) [![](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/insta.jpg)](https://www.instagram.com/iridex_glaucoma)\n\n  * [Home](http://www.iridex.com/Default.aspx?tabid=56)\n  * [Products](http://www.iridex.com/Default.aspx?tabid=58)\n    * [Lasers](http://www.iridex.com/Default.aspx?tabid=102)\n      * [Cyclo G6](http://iridex.com/Products/Lasers/CYCLOG6MicroPulseP3.aspx)\n      * [IQ 532](https://iridex.com/Default.aspx?tabid=103)\n      * [IQ 577](https://iridex.com/Default.aspx?tabid=104)\n      * [OcuLight](https://iridex.com/Default.aspx?tabid=132)\n    * [Retina Delivery Devices](https://iridex.com/Default.aspx?tabid=107)\n      * [LIO](https://iridex.com/Default.aspx?tabid=384)\n      * [TxCell](https://iridex.com/Products/LaserDeliveryDevices/GlaucomaDevices/micropulsep3.aspx)\n    * [Glaucoma Devices](http://www.iridex.com/Default.aspx?tabid=184)\n      * [MicroPulse P3 Device](http://iridex.com/Products/Lasers/CYCLOG6MicroPulseP3.aspx)\n      * [Revised MicroPulse P3](https://iridex.com/Products/GlaucomaDevices/micropulsep3.aspx)\n      * [G-Probe](http://iridex.com/Default.aspx?tabid=112)\n      * [G-Probe Illuminate](http://iridex.com/Default.aspx?tabid=314)\n      * [MicroPulse Laser Trabeculoplasty (MLT) Lens](http://iridex.com/Default.aspx?tabid=178)\n    * [Retinal Surgical Instruments](http://iridex.com/Default.aspx?tabid=89)\n      * [Laser Probes](http://iridex.com/Default.aspx?tabid=208)\n      * [Consumables](http://iridex.com/Default.aspx?tabid=182)\n    * [Veterinary](http://www.iridex.com/Default.aspx?tabid=101)\n    * [ENT](http://www.iridex.com/Default.aspx?tabid=113)\n    * [Accessories](http://www.iridex.com/Default.aspx?tabid=350)\n      * [Vexio Cart](http://www.iridex.com/Default.aspx?tabid=351)\n  * [MicroPulse](http://www.iridex.com/Default.aspx?tabid=86)\n  * [Physician Education](http://www.iridex.com/Default.aspx?tabid=84)\n    * [Glaucoma](http://www.iridex.com/Default.aspx?tabid=158)\n      * [Library](http://www.iridex.com/Default.aspx?tabid=362)\n      * [MicroPulse P3 - CYCLO G6](http://www.iridex.com/Default.aspx?tabid=228)\n      * [TSCPC G-Probe](http://www.iridex.com/Default.aspx?tabid=120)\n      * [Trabeculoplasty (MLT)](http://www.iridex.com/Default.aspx?tabid=123)\n    * [Retina](http://www.iridex.com/Default.aspx?tabid=159)\n      * [Age-Related Macular Degeneration](http://www.iridex.com/Default.aspx?tabid=258)\n      * [Central Serous Chorioretinopathy](http://www.iridex.com/Default.aspx?tabid=149)\n      * [Diabetic Macular Edema ](http://www.iridex.com/Default.aspx?tabid=117)\n      * [ME due to RVOs](http://www.iridex.com/Default.aspx?tabid=161)\n      * [ROP](http://www.iridex.com/Default.aspx?tabid=202)\n      * [Vitreoretinal Surgery](http://www.iridex.com/Default.aspx?tabid=118)\n    * [Testimonials](http://www.iridex.com/Default.aspx?tabid=299)\n    * [Certification](http://www.iridex.com/Default.aspx?tabid=376)\n    * [Webinars](http://www.iridex.com/Default.aspx?tabid=288)\n    * [Seminars](http://www.iridex.com/Default.aspx?tabid=292)\n    * [Articles](http://www.iridex.com/Default.aspx?tabid=346)\n    * [Clinical Library](javascript:void\\(window.open\\('https://iridexsupport.zendesk.com/hc/en-us'\\)\\))\n    * [Reimbursement Calculator](http://www.iridex.com/Default.aspx?tabid=190)\n    * [Manuals](http://www.iridex.com/Default.aspx?tabid=385)\n  * [Patient Education](http://www.iridex.com/Default.aspx?tabid=85)\n    * [Treat My DME](javascript:void\\(window.open\\('http://treatmydme.com/'\\)\\))\n    * [Treat My Glaucoma](javascript:void\\(window.open\\('http://treatmyglaucoma.com/'\\)\\))\n    * [Find A Physician](http://www.iridex.com/Default.aspx?tabid=155)\n  * [Contact](http://www.iridex.com/Default.aspx?tabid=137)\n    * [Contact Us](http://www.iridex.com/Default.aspx?tabid=91)\n    * [Ask A Question](http://www.iridex.com/Default.aspx?tabid=92)\n    * [Schedule A Demo](http://www.iridex.com/Default.aspx?tabid=93)\n    * [Request A Quote](http://www.iridex.com/Default.aspx?tabid=94)\n    * [Order EndoProbe®](http://www.iridex.com/order-endoprobes/index.html)\n    * [International Distributors](http://www.iridex.com/Default.aspx?tabid=116)\n\n\n\n#  Proxy Online \n\n**Notice of 2022 Annual Meeting of Stockholders** **Date:** 6/15/2022 **Location:** IRIDEX | 1212 Terra Bella Avenue | Mountain View, CA 94043 **Record Date:** 4/18/22 **Proposals to be voted upon:**\n\n  1. Election of Director Nominees: David I. Bruce, Nandini Devi, Robert Grove, Beverly A. Huss, Kenneth E. Ludlum and Scott Shuda\n  2. To ratify the appointment of BPM LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2022\n  3. To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement\n\n[Proxy Statement 2022](/static-files/d76f4e5a-d9a9-41f2-8f6a-542eabcd1a8f)  \n---  \n  \n##  Products\n\n[Lasers](http://www.iridex.com/Products/Lasers.aspx) [Delivery Devices](http://www.iridex.com/Products/DeliveryDevices.aspx) [Retina Consumables](http://www.iridex.com/Products/RetinaConsumables.aspx) [Glaucoma Device](http://www.iridex.com/Products/GlaucomaConsumables/G-Probe.aspx) | \n\n## Resources\n\n[Physician Information](http://www.iridex.com/PhysicianEducation.aspx) [Patient Information](http://www.iridex.com/PatientEducation.aspx) [Clinical Library](http://www.iridex.com/PhysicianEducation/ClinicalLibrary.aspx) | \n\n## About IRIDEX\n\n[Overview](http://www.iridex.com/Company/tabid/95/Default.aspx) [News](http://www.iridex.com/News.aspx) [Events](http://www.iridex.com/Events.aspx) [Contact Us](http://www.iridex.com/Contact.aspx) | \n\n## Company\n\n[Investors](/) [Offices/Contact](http://www.iridex.com/Contact/InternationalDistributors.aspx) [Careers](http://www.iridex.com/Company/Careers/tabid/96/Default.aspx)  \n---|---|---|---  \n[![twitter](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-twitter.jpg)](http://twitter.com/iridex) [![facebook](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-fb.jpg)](http://www.facebook.com/IRIDEX) [![linkedin](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-linkedin.jpg)](http://www.linkedin.com/company/iridex) [![youtuber](/sites/g/files/knoqqb14341/themes/site/nir_pid1324/client/images/icon-youtube.jpg)](http://www.youtube.com/user/IRIDEXCorp)  \n---  \n  \nCopyright 2024 by Iridex Corporation\n\n[Terms Of Use](http://www.iridex.com/terms.aspx) | [Privacy Statement](http://www.iridex.com/privacy.aspx)\n"
        }
      ]
    }
  ]
}